Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer

Luca Colucci-D'Amato 1,2,*, Luisa Speranza 3 and Floriana Volpicelli 4

1 Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy
2 InterUniversity Center for Research in Neurosciences (CIRN), University of Campania "Luigi Vanvitelli”, 80131 Naples, Italy
3 Department of Neuroscience, Albert Einstein College of Medicine, New York, NY 10461, USA; luisa.speranza@einsteinmed.org
4 Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy; floriana.volpicelli@unina.it

Received: 29 September 2020; Accepted: 19 October 2020; Published: 21 October 2020

Abstract: Brain-derived neurotrophic factor (BDNF) is one of the most distributed and extensively studied neurotrophins in the mammalian brain. BDNF signals through the tropomycin receptor kinase B (TrkB) and the low affinity p75 neurotrophin receptor (p75NTR). BDNF plays an important role in proper growth, development, and plasticity of glutamatergic and GABAergic synapses and through modulation of neuronal differentiation, it influences serotonergic and dopaminergic neurotransmission. BDNF acts as a paracrine and autocrine factor, on both pre-synaptic and post-synaptic target sites. It is crucial in the transformation of synaptic activity into long-term synaptic memories. BDNF is considered an instructive mediator of functional and structural plasticity in the central nervous system (CNS), influencing dendritic spines and, at least in the hippocampus, the adult neurogenesis. Changes in the rate of adult neurogenesis and in spine density can influence several forms of learning and memory and can contribute to depression-like behaviors. The possible roles of BDNF in neuronal plasticity highlighted in this review focus on the effect of antidepressant therapies on BDNF-mediated plasticity. Moreover, we will review data that illustrate the role of BDNF as a potent protective factor that is able to confer protection against neurodegeneration, in particular in Alzheimer’s disease. Finally, we will give evidence of how the involvement of BDNF in the pathogenesis of brain glioblastoma has emerged, thus opening new avenues for the treatment of this deadly cancer.

Keywords: BDNF; miRNAs; neurogenesis; synaptic plasticity; depression; neurodegeneration; glioblastoma

1. Introduction

The neurotrophin BDNF is one of the most studied and well characterized neurotrophic factors in the CNS. It regulates many different cellular processes involved in the development and maintenance of normal brain function by binding and activating the TrkB, a member of the larger family of Trk receptors. In the brain, BDNF is expressed by glutamatergic neurons [1], glial cells, such as astrocytes isolated from the cortex and hippocampus, but not from the striatum [2], and microglia [3]. During embryogenesis, BDNF–TrkB signaling promotes the differentiation of cortical progenitor cells and later promotes differentiation of cortical progenitor cells into neurons (i.e., neurogenesis) [4]. Several lines of evidence also suggest that the BDNF/TrkB signaling is involved in adult neurogenesis.
in the hippocampus with differing effects in the dentate gyrus (DG) and subventricular zone (SVZ) [5]. Adult neurogenesis in the dentate gyrus is enhanced by voluntary exercise, exposure to an enriched environment, and chronic antidepressant administration. Recently, it has also been proposed that caloric restriction and intermittent fasting in particular, appears to positively modulate hippocampal neurogenesis and BDNF [6]. The connection between BDNF and the modulation of hippocampal neurogenesis by external stimuli is a topic that has been extensively studied in recent years [7]. It has been demonstrated that voluntary physical exercise, like an enriched environment, increases expression of BDNF in the hippocampus [8], as well as hippocampal neurogenesis [9]. Physical exercise is one particularly effective strategy for increasing circulating levels of BDNF [10,11] and improving brain function [12–14].

In addition, studies also show that BDNF is an important regulator of synaptic transmission and long-term potentiation (LTP) in the hippocampus and in other brain regions. The effects of BDNF on LTP are mediated by the TrkB receptor. Especially in the hippocampus, this neurotrophin is thought to act on both the pre- and post-synaptic compartments, modulating synaptic efficacy, either by changing the pre-synaptic transmitter release, or by increasing post-synaptic transmitter sensitivity [15,16] to induce a long-lasting increase in synaptic plasticity. Additionally, converging data now suggest a role for BDNF in the pathophysiology of brain-associated illnesses. Deficits in BDNF signaling are reported to contribute to the pathogenesis of several major diseases, such as Huntington’s disease, Alzheimer’s disease (AD), depression, schizophrenia, bipolar, and anxiety disorders. Thus, manipulating the BDNF signaling may present a viable approach to treat a variety of neurological and psychiatric disorders. BDNF protein is also detectable outside of the nervous system in several non-neuronal tissues, such as in endothelial cells [17,18], cardiomyocytes [19], vascular smooth muscle cells [17], leukocytes [20], platelets [21,22], and megakaryocytes [19]. Therefore, it may also be involved in cancer, angiogenesis, reduction of glucose production from the liver [23], and in the uptake of glucose in peripheral tissues (see [24] for review). In addition, BDNF promotes the development of neuromuscular synapses and is required for fiber-type specification, suggesting a potential role as a therapeutic target in muscle diseases [25]. In this review, first we examine the currently known mechanisms of BDNF signaling, information essential for the creation of BDNF-based therapeutics. Next, we focus on the effects of antidepressants on BDNF-mediated plasticity. Additionally, we highlight the function of BDNF as a potent factor capable of conferring protection against neurodegeneration. Finally, we touch on the newly emerging role of BDNF in the pathogenesis of brain gliomas.

2. The Human BDNF Gene: Transcripts and Variants

2.1. BDNF Transcripts

The BDNF gene codes for a neurotrophin that is highly expressed in the CNS [26]. At the beginning of 2000s, the only data available about the structure and regulation of the BDNF gene were from Timmusk and colleagues, which identified in rats four 5’ exons linked to separate promoters and one 3’ exon encoding the preproBDNF protein [27–29]. These four BDNF promoters owned multiple points of BDNF mRNA regulation and suggested an activity-dependent regulation [28–31]. Further studies, published in 2007, clarified that BDNF has a complex gene structure with 11 different exons in humans, nine different exons in rodents, and nine alternative promoters for both groups [32,33]. Despite this complexity, the coding sequence is located in exon IX in both human and rodents. The latter includes the common sequence that encodes for the proBDNF protein. All other exons are untranslated regions with a start codon present in exons I, VII, VIII, and IX of the human BDNF gene. Exon IX is present in all BDNF mRNA isoforms. It is supposed that the nine alternative promoters can regulate the complex spatio-temporal expression of BDNF gene and allow BDNF to respond to a greater variety of stimuli. For instance, in human brain tissues, all exons are expressed, but to different degrees and in different brain structures [33]. Human heart tissue, instead, expresses high levels of BDNF isoforms containing exon IV and exon IX [33].
Currently, two BDNF promoters, promoter I and promoter IV, have been well characterized for their response after the activation of the L-type voltage gated calcium channel (L-VGCC) or the n-methyl-d-aspartate (NMDA) receptor. Activation of L-VGCC and NMDA receptors mediate intracellular Ca$^{2+}$-signaling and regulate several aspects of brain functions (for review [34,35]). Promoter I is more responsive to neuronal activity and induces activity-dependent expression of BDNF in vitro and in vivo. It contains calcium-responsive elements (CaREs) and cyclic adenosine monophosphate (cAMP)/calcium response element (CRE) [29,36–38]. Deletion of CRE or overexpression of dominant negative of CREB (cAMP-response element-binding protein) significantly impairs rat BDNF promoter I response to neuronal depolarization [38]. Human BDNF promoter I is similar to rat promoter, since an orthologous CRE-like element is also present [39]. However, mutation of this site did not affect human BDNF promoter I response to depolarization [39]. Human BDNF promoter I also contains an activator protein 1 (AP1) -like element and an asymmetric E-box-like element [39]. Mutation in E-box-like element reduces human BDNF promoter I induction, impairing the response to neuronal depolarization [39].

Another highly characterized BDNF promoter is the BDNF promoter IV that contributes significantly to activity-dependent BDNF transcription. Human and rat BDNF promoter IV are similar. In this promoter, three CaREs and three other regulatory elements involved in regulating rat BDNF promoter response to NMDA receptor activation have been identified [40]. NMDA receptor activation is capable of triggering BDNF exon IV transcription through a protein-signaling cascade requiring extracellular signal-regulated kinase (ERK), Ca$^{2+}$/calmodulin-dependent protein kinase (CaMK) II/IV, phosphoinositide 3-kinases (PI3K), and phospholipase C (PLC). BDNF exon IV expression also seems capable of further stimulating its own expression through TrkB activation [41]. Additionally to the CaREs, two positive regulators have been identified: the NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) [42] and NFAT (nuclear factor of activated T-cells) binding sites [30,43]. In contrast to these positive regulators, BDNF promoter IV also contains a negative regulatory element, the class B E-box. This is a binding site for a basic helix-loop-helix protein, BHLH2, a suppressor of the bHLH gene superfamily [43,44]. NMDA treatment is able to remove BHLH2 binding to the E-box and to increase rat BDNF promoter IV activity [43,44]. Disruption of BDNF promoter IV in mice significantly reduced the number of parvalbumin GABAergic neurons in the prefrontal cortex and impaired GABAergic activity [45]. These mice displayed depression-like behavior such as anhedonia-like behavior and increased latency to escape in the learned helplessness test [45]. Further evidence suggests a relationship between stress exposure and epigenetic regulation of BDNF promoter IV with the development of psychiatric disorders. Specifically, changes in BDNF promoter IV methylation levels are implicated in depression [46,47]. Preliminary evidence has demonstrated that patients with major depressive disorder (MDD) present a hypomethylation of the CpG-87 site of the promoter IV region of BDNF gene and are less likely to benefit from antidepressants [47,48]. In addition, BDNF disruption from promoter IV-derived transcripts impairs fear expression in mice, suggesting that cells expressing BDNF from promoter IV critically regulate hippocampal-prefrontal plasticity during fear memory [49,50].

2.2. miRNAs and BDNF

MicroRNAs (miRNAs) are a class of evolutionary conserved small non-coding single-strand RNA molecules, 18–25 nucleotide long, able to bind to 3’ untranslated regions (3’ UTR) of target mRNAs and promote their degradation or suppress their translation into proteins. MiRNAs are expressed abundantly within the nervous system in a tissue-specific manner and are crucial players in several biological processes, including neurogenesis, neuronal maturation, synapse formation, axon guidance, neurite outgrowth and neuronal plasticity [51–53]. Accumulating data indicate that synthesis of BDNF may be affected by miRNAs, indeed, a regulatory negative feedback loop between BDNF and miRNAs exists. That is, while BDNF treatment stimulates neuronal miRNAs expression, miRNAs generally inhibit the expression of BDNF [54]. This negative feedback loop is maintained in a state of equilibrium.
in normal cells. Alterations in miRNAs or in BDNF contribute to the pathogenic mechanisms involved in neurodegenerative diseases or neuropsychiatric disorders.

A number of recent studies, obtained from high throughput sequencing screening of different brain regions or from neurological disorders, have identified seven miRNAs (miR-15a, miR-206, miR-155-5p, miR-16, miR-103-3p, miR-330-3p, Let-7a-3p) correlated with BDNF [55]. Previous data published by Schratt et al. reported the involvement of miR-134 in BDNF-regulated dendritic spine size in hippocampal neurons. They demonstrate that miR-134 negatively regulates the spine size via repressing the translation of LIM kinase 1, which is known to regulate dendritic structures. BDNF is able to relieve the inhibition of LIM kinase 1 translation, and in this manner contribute to synaptic development, maturation and/or plasticity [56]. Recently, Baby et al. [57] found that miR-134 mediates post-transcriptional regulation of CREB1 and BDNF, as previously described by Gao et al. [58], who demonstrated that mutant mice lacking Sirtuin 1 (SIRT1) catalytic activity shows reduction in both CREB and BDNF proteins and upregulation of miR-134. Thus, higher levels of miR-134 negatively regulate synaptic plasticity [58]. MiR-134-mediated post-transcriptional regulation of CREB1 and BDNF prevents cognitive deficits in chronic unpredicted mild stress model (CUMS) [59]. At the same time, data published by Xin and coworkers [60] demonstrate that miR-202-3p silencing reduces the damage to hippocampal nerve in CUMS rats through the upregulation of BNDF expression. miRNAs could be an effective target also for the treatment of depression. Recent data demonstrate that miR-124-mediated post-transcriptional regulation of CREB1 and BDNF can improve depression-like behavior in a rat model [61]. Instead, miR-153 through the inhibition of activation of the JAK-STAT signaling pathway improves BDNF expression and influences the proliferative ability of hippocampal neurons in autistic mice [62].

In vitro studies have also allowed analysis of the effect of neurotoxins or anesthetic agents on miRNAs expression and in turn, on BDNF expression. For instance, differentiated PC12 cells, treated with 1-methyl-4-phenylpyridinium (MPP), show upregulation of miR-34a, miR-141, and miR-9, suggesting that perturbed expression of them may contribute to Parkinson’s disease (PD)-related pathogenic processes, probably by affecting the expression of B-cell lymphoma 2 (BCL2), BDNF, and SIRT1 as potential targets [63].

Instead, studies in vitro on embryonic stem cell-derived neurons demonstrated that inhibition of miR-375 and miR-107 ameliorates ketamine-induced neurotoxicity via inverse regulation of the BDNF gene [64,65].

In summary, understanding the different functions of the various BDNF transcripts, the modulation of the expression of specific exons, and investigating the function of the BDNF-related miRNAs may represent a promising strategy to restore enduring changes in gene expression in response, for example, to environmental insults. This, in turn, might open new therapeutic perspectives for the treatment of neurodegenerative and neuropsychiatric disorders.

2.3. Biology of BDNF

Synthesis and maturation of BDNF is a multistage process, involving the formation of several precursor isoforms. The BDNF protein, discovered in 1982 [66], is a highly conserved protein of 247 amino acids, synthesized and folded in the endoplasmic reticulum as preproBDNF (32–35 kDa). Upon translocation to the Golgi apparatus, the signal sequence of the preregion is rapidly cleaved, and the isoform proBDNF (28–32 kDa) is generated [67]. The proBDNF is further cleaved to reach the mature isoform (mBDNF, 13 kDa) [67,68]. Intracellular proteolytic cleavage of proBDNF may occur by the subtilisin-kexin family of endoproteases such as furin, or in intracellular vesicles by convertases [69,70] (Figure 1).
Figure 1. Brain-derived neurotrophic factor (BDNF) protein structure. The proBDNF consists of three sequences: signal sequence (s.s), pro-domain, and mature domain. The intra- or extracellular cleavage of proBDNF generates functionally active isoforms: BDNF pro-peptide and mature BDNF (mBDNF), each of which exhibits a characteristic affinity to a specific type of receptor. Arrowheads indicate known protease cleavage sites involved in the processing of mature BDNF. The position of the single nucleotide polymorphism (rs6265, Val66Met) and the substitution of valine (Val) in methionine (Met) at codon (aa) 66 in the human BDNF gene is indicated by an arrow.

Extracellular cleavage of proBDNF is determined by plasmin [71] and matrix metalloproteases 2 and 9 (MMP2 and MMP9) [72,73]. Depending on the cell type, BDNF can be secreted in a constitutive or activity-dependent manner [74]. In neuronal cells, both proBDNF and mBDNF are released following cell membrane depolarization [75–77]. The balance of proBDNF and mBDNF depends on the particular stages of brain development and regions. In the early postnatal period, the concentration of proBDNF is higher and may be considered as an important factor modulating brain function; while mBDNF prevails in adulthood and is important for processes occurring in adulthood, such as neuroprotection and synaptic plasticity [78]. Both proBDNF and mBDNF are active, eliciting opposing effects via the p75 neurotrophin receptor (p75NTR), a member of the tumor necrosis factor (TNF) receptor family and TrkB receptor, respectively. In resting form, both types of receptor are located in the membrane of intracellular vesicles. Stimulation with cAMP, Ca\(^{2+}\), or electrical impulse initiates their transfer and fusion with the cellular membrane [79,80].

The mature domain of proBDNF interacts preferentially with p75NTR, mediating synaptic pruning in the prenatal brain [81]. ProBDNF, through its pro-domain, can also interact with the sortilin receptor or other vacuolar protein sorting 10 protein (Vps10p) (Figure 2). Thus, proBDNF binding to specific receptors triggers signaling pathways, which can determine neuronal fate via promoting their death or survival [82,83]. The proBDNF/p75NTR/sortilin binding complex initiates signaling cascades leading to the activation of c-Jun amino terminal kinase (JNK). This pathway is involved in neuronal apoptosis [82,83]. High levels of p75NTR expression are detected during brain development and post-traumatic recovery [84]. When mature domain of BDNF binds to p75NTR, the RIP2 (serine/threonine-protein kinase 2)/TRAF6 (tumor necrosis factor receptor associated factor 6)-mediated pathway is initiated, which leads to NF-kB activation [82,85]. The activation of NF-kB promotes neuronal survival and maintenance during brain development [85]. In addition, p75NTR interacts also with the Ras homologous (Rho) protein family. This pathway is reported to regulate neuronal growth cone development and motility [85].
mBDNF binds with the high-affinity TrkB receptor, the receptor dimerizes, and the intracellular tyrosine residues are autophosphorylated [86]. Phosphorylated-TrkB activates several enzymes: PI3K, mitogen-activated protein kinase (MAPK), PLC-γ, and guanosine triphosphate hydrolases (GTP-ases) of the Rho gene family [87–89]. mBDNF-TrkB-signaling pathways regulate multiple events, such as apoptosis and survival of neurons [90–92], dendritic growth [93–96], spine maturation [97]. Phosphorylated-TrkB activates several enzymes: PI3K, mitogen-activated protein kinase (MAPK), PLC-γ. This pathway activates the JNK-associated pathway that promotes programmed cell death, or the receptor-interacting serine/threonine-protein kinase 2 (RIP2) /TRAF6-mediated pathway is initiated. Multi-subunit IκB kinase (IKK) phosphorylates (orange dot) the inhibitor of kB (IkB) protein, which results in dissociation of IkB from NF-κB. The activated nuclear factor kappa B (NF-κB) is then translocated into the nucleus where it binds to specific sequences of DNA and promotes neuronal survival and maintenance. In addition, p75NTR interacts with the Rho family of proteins, whose activation mediates the activity of Rho-associated protein kinase (ROCK), which subsequently leads to activation of the AKT pathway, involved in cytoskeletal remodeling. The mBDNF/TrkB receptor complex triggers signaling pathways associated with activation of phosphatidylinositol 3-kinase (PI3K), phospholipase C gamma (PLC-γ), and GTP-ases of the Rho family, involved in survival, plasticity and neurite outgrowth, transcription regulation, and synaptic plasticity.
such as apoptosis and survival of neurons [90–92], dendritic growth [93–96], spine maturation and stabilization, development of synapses [96–98], learning- and memory-processes-dependent synaptic plasticity [99,100].

PI3K/Akt-related pathway exerts antiapoptotic and pro-survival activity and modulates NMDA receptor-dependent synaptic plasticity [101–103]. The PI3K/Akt/mTOR cascade enhances dendritic growth and branching through regulation of protein synthesis and cytoskeleton development [104,105].

The MAPK/Ras-signaling cascade regulates protein synthesis during neuronal differentiation [85] and is also required for the activation of ERK 1/2 and CREB [106,107]. This pathway is crucial not only for early response gene expression (e.g., c-Fos), but also for cytoskeleton protein synthesis (e.g., Arc and cypin) [87], as well as dendritic growth and branching in hippocampal neurons [94,108].

The PLC-γ-dependent pathway evokes activation of CAM kinase and protein kinase C (PKC), which subsequently increases the 1,2-diacylglycerol (DAG) and Ca\(^{2+}\) ion concentrations [89]. The PKC-dependent pathway is reported to enhance synaptic plasticity [85] (Figure 2).

In summary, the specific role of BDNF in the regulation of numerous brain physiological processes depends on the interaction of its isoforms with different types of receptors. This, in turn, elicits the activation of signaling pathways that are critical for processes of brain development, synaptic plasticity, and protection and/or regeneration after damage. Perturbation of the BDNF synthesis, resulting in dysfunctions of its signaling cascades, may be responsible for triggering several pathological processes.

### 2.4. The Human BDNF Variant Val66Met

BDNF level in the peripheral tissues, brain, and blood may be also affected by gene polymorphism. The pro-domain of BDNF is the locus of a functional human BDNF polymorphism (SNPs) Val66Met, also known as rs6265 or G196A polymorphism [109]. This point mutation causes a substitution of Valine (Val) to Methionine (Met) at codon 66 (Val66Met) in the pro-domain of BDNF (Figure 1). The Val66Met polymorphism does not exist in the mouse or other model organisms. Thus, multiple studies aim to mimic the function of BDNF Val66Met in cellular models or in genetically engineered mouse models. The BDNF Val66Met variant was first identified in the late 1990s and in 2002 the first two genetic studies investigating the BDNF Val66Met polymorphism in the pathogenesis of neurodegenerative disease were published [110,111]. The functionality of BDNF Val66Met variant was only confirmed in 2003 [112], where BDNF Val66Met polymorphism was shown to disrupt the episodic memory in humans. In addition, Egan et al. [112] also demonstrated that in hippocampal cultures BDNF Val66Met polymorphism did not alter BDNF expression per se, but the perisomatic localization of BDNF. Then, in 2005 it was discovered that the BDNF Val66Met substitution also disrupts the sortilin-binding site, impairing activity-mediated secretion of BDNF [113]. Likewise, the BDNF Val66Met substitution also disrupts the translin-binding site, which impairs dendritic targeting of BDNF mRNA [114]. Thus, the principle molecular mechanism associated with the BDNF Val66Met polymorphism is the deficient activity-dependent release of BDNF, which consequently impacts the efficiency of BDNF-TrkB signaling [113]. Following the demonstration that this SNP was functionally relevant over the past 18 years, more than 1700 studies have investigated the effects of this polymorphism on brain function in health, as well as in diseases, particularly in neuropsychiatric disorders [115,116]. The BDNF Val66Met polymorphism has been associated with cerebral cortex plasticity [117,118], with gray matter structures [119,120], or white matter integrities and structural networks [121,122]. More specifically, BDNF Val66Met polymorphism is associated with cognitive processes [112,123–127], and cognitive impairment in neurodegenerative disease, such as Parkinson’s disease (PD) [128,129] and AD [130,131], and even more with several brain disorders, including MDD and bipolar disorder [132–137], epilepsy [138–140], schizophrenia [125,141–144], aging and dementia [145] and stroke [117,146,147]. Met66, but not Val66, BDNF pro-domain can induce the growth cone retraction in young hippocampal neurons [148]. Although many studies have demonstrated the possible genetic effects of this BDNF polymorphism in diseases or brain function,
other articles have failed to replicate the findings. The discrepancies of BDNF Val66Met genetic studies may result from many factors such as environmental factors, ethnicity, age, and sex.

3. Neuroplasticity in MDD: The Effects of Antidepressant Therapies

3.1. Major Depressive Disorder

Major depressive disorder is one of the most prevalent and debilitating psychiatric disorders with high impact on the quality of life and negative effects on mood, behavior, and cognition [149]. Over the past few decades, several mechanisms have been investigated in the pathophysiology of MDD, including altered serotonergic, noradrenergic, dopaminergic, and glutamatergic systems, increased inflammation, hypothalamic-pituitary-adrenal axis abnormalities, vascular changes, and decreased neurogenesis and neuroplasticity. In particular, a decrease in serotonergic neurotransmission is regarded as the main etiopathogenetic mechanism occurring in depressed patients. Thus, the most common drugs used to treat MDD are serotonin reuptake inhibitor (SSRI) that block SERT and thus increase serotonin in the raphe nucleus at post-synapse. Therefore, a misbalance in the serotonin production and/or release is believed to play a central role in determining MDD. This led to finding, by means of genetic, proteomic and pharmacological tools, molecules able to increase the expression of serotonin in neurons by modulating neural genes or proteins [150–152]. Among these molecules, TPH2, the rate-limiting enzyme responsible for brain serotonin biosynthesis, plays a crucial role and is amenable of genetic and pharmacological manipulation [153,154]. Nevertheless, in 1997 Duman and Nestler formulated the neurotrophin hypothesis of depression [155]. This theory is now supported by studies demonstrating a decrease in BDNF mRNA and protein levels in postmortem critical regions, such as the hippocampus, prefrontal cortex and amygdala, in patients with MDD compared to controls.

3.2. BDNF and Neuronal Plasticity

Brain development occurs through coordinated processes of neuro- and gliogenesis, formation of neuronal projections and synaptogenesis, and programmed cell death and elimination of improperly formed connections, together resulting in the formation of the functionally and morphologically adjusted structure of the adult brain [156,157]. Neuroplasticity or brain plasticity is the ability of the nervous system to reorganize its structure, function, and connections in response to extrinsic or intrinsic stimuli [158]. Neuronal plasticity in rodents has been well-documented during the last decades, whereas neuroplasticity in the human brain largely remains indirect, mostly because of methodological limitations as well as ethical constraints. Neuronal plasticity includes different mechanisms excellently reviewed by Castren [159]. One of these is the neurogenesis, i.e., the formation of newborn neurons in proliferative areas. There is solid evidence that neurogenesis occurs in the adult mammalian brain. In rodent adult brains, neurogenesis is mainly restricted to the subventricular zone and the subgranular zone of the dentate gyrus in the hippocampus and olfactory bulbs [156]. An accumulating body of evidence indicates that BDNF is involved in the regulation of migration of neuronal progenitors along the rostral migratory stream and neuronal settlement in the olfactory bulb [160] and also acts during the later stages of neurogenesis [161,162].

Neuronal plasticity is extensively studied during critical periods, a time window during the early phase of brain development, when neuronal circuits are noticeably sensitive to being shaped by external stimuli and experience, producing permanent and large-scale changes to neural circuits. The same circuits can be shaped by experience later in life, but to a lesser degree. After the ending of critical periods, neuronal plasticity and changes in network structure are more restricted. However, recent data indicate that several drugs used for the treatment of neuropsychiatric disorders can directly induce plasticity and reactivate a critical period-like plasticity in the adult brain. The first functional evidence for the role of neurotrophins in plasticity was obtained in the visual cortex. The observation that BDNF synthesis in the visual cortex is regulated by visual stimulation made BDNF the prime candidate for this activity-dependent regulated factor [163–165]. In transgenic mice with early overexpression of
BDNF, an accelerated onset and end of the critical period and precocious maturation of inhibitory circuits was observed. Conversely, mice raised in the dark and resulting in lower levels of BDNF showed a delayed visual plasticity [166,167]. In addition, a disruption in the binding between promoter regions of BDNF exon IV and cAMP response element-binding protein (CREB) results in decreased inhibitory input [168], which impairs the critical period plasticity.

3.3. BDNF and Synaptic Plasticity

Another mechanism involved in neuronal plasticity is the modification of mature neuronal morphology, involving axonal and dendritic arborization and pruning, an increase in spine density, and synaptogenesis [169]. Epigenetic mechanisms involved in the transcriptional regulation of genes also can contribute to synaptic plasticity. Several in vitro and in vivo studies analyzed the effects of BDNF on plasticity. Cazorla et al. proved that 48 h of BDNF stimulation in PC12 cells, transfected with TrkB, increased neurite outgrowth compared to the non-treated cells [170]. Interestingly, BDNF stimulation was able to promote dendritic outgrowth and spine formation [171,172] in primary hippocampal cells grown in B27-deprived medium. This neuroplastic effect is probably achieved through the activation of intracellular-signaling cascades [173,174]. Recent data suggest that intracellular overexpression of BDNF in hippocampal developing neurons induces maturation of excitatory and inhibitory synapses, with respect to exogenous application of BDNF [175]. BDNF mice lacking BDNF die during the second postnatal week [176] and BDNF deficit causes inhibition of dendritic arborization [92,177] and reduction of expression of genes functionally related to vesicular trafficking and synaptic communication [178]. Instead, heterozygous BDNF mice survive into adulthood and BDNF is required for several forms of LTP, the main mechanism mediating plasticity [179]. At morphological level, these mice display a specific hippocampal volume reduction [180] similar to that observed in heterozygous TrkB mice [181,182], but in contrast to p75NTR-deficient mice [183]. These findings suggest a link between hippocampal volume and BDNF-mediated TrkB signaling [181,182]. Over the last years, BDNF has been extensively studied as an important regulator of synaptic transmission and LTP in the hippocampus and in other brain regions. The effects of BDNF in LTP are mediated by TrkB receptors. In particular, in the hippocampus the neurotrophin is thought to act at pre- and post-synaptic levels, modulating synaptic efficacy either by changes in pre-synaptic transmitter release, or by increased post-synaptic transmitter sensitivity (see e.g., [15,16]) to induce a long-lasting increase in synaptic plasticity. This depends on individual circumstances. Thus, BDNF can be: (i) either, a mediator or a modulator of synaptic plasticity, (ii) both, a neurotransmitter that acts both at pre- and post-synaptic level simultaneously at the same individual synapse. Recent data published from Lin et al. revealed that in CA3 or CA1 regions anterograde BDNF-TrkB signaling is involved in LTP induction, while anterograde and retrograde BDNF-TrkB signaling contributes to LTP maintenance. BDNF in both pre-synaptic and post-synaptic terminals modulate basal neurotransmission and pre-synaptic TrkB, probably regulating pre-synaptic release [184]. In addition, it has also been shown that BDNF regulates the transport of mRNAs along dendrites and their translation at the synapse. These processes occur by modulating the initiation and elongation phases of protein synthesis, and by acting on specific miRNAs [100]. Local protein synthesis responds with rapid and subtle modulation of the proteome to remodel the synaptic regions in response to stimuli [185]. Protein turnover is required for synaptic plasticity, and BDNF-signaling has been also described as a crucial regulator for maintaining the baseline autophagic activity in the brain. BDNF deficiency causes an uncontrolled rise in autophagic degradation [186].

BDNF is one of the most studied synaptic molecules that efficiently modify synaptic strength and can act as a mediator, modulator, or instructor of synaptic plasticity. Specific changes in dendritic spines, as well as in adult hippocampal neurogenesis, can be correlated to several forms of learning and memory. BDNF is one of the most inspiring molecules to better understand the disadvantageous synaptic learning underlying the etiology of depression, accompanied by declines in the rate of adult neurogenesis and in spine densities [181].
3.4. BDNF in Depressed Patients

BDNF protein and TrkB receptor are detectable in several non-neuronal tissues, including endothelial cells [17,18], cardiomyocytes [19], vascular smooth muscle cells [17], leukocytes [20], megakaryocytes [19], and platelets [21,22]. Serum BDNF has been clearly demonstrated to originate from the progenitors of platelets [21]. Platelets are the major source of peripheral BDNF and are important for storing the BDNF secreted from other tissues [187]. Over the last years, there has been a great interest in peripheral BDNF measures in relation to psychiatric illness. It has been studied as biomarker reflecting these disorders [188,189]. However, there is no evidence that serum BDNF is related to brain BDNF and neuroplasticity. Nevertheless, the low serum concentration of BDNF has often been associated with the pathophysiology of MDD [190–192]. An aspect to consider is if the serum BDNF levels are dependent on the release of BDNF from platelets [193]. The significance of the lower BDNF levels in depression is currently unclear. The temporal correlation between serum BDNF levels and the antidepressant effect seems to be indirect: ketamine and electroconvulsive shock treatment increase serum BDNF levels only gradually, while their antidepressant effect appears quickly [194]. There are two studies that directly observed a reduction of BDNF levels in platelets of patients with MDD [195,196]. Another study showed that BDNF levels of platelet were significantly decreased compared to the controls. In this study, the BDNF levels were normalized compared to control with SSRIs treatment [197]. Taken together, these studies strongly suggest that changes in serum BDNF levels reflect altered BDNF release from blood platelets. Thus, given the similarities in the regulation of BDNF synthesis between megakaryocytes and neurons, there may be parallels between the brain, BDNF in serum, and release. Nevertheless, within the CNS a reduction in BDNF and TrkB expression has been reported in the hippocampus and prefrontal cortex of post-mortem brain tissues of suicide victims [198,199]. In addition, several meta-analyses data confirm the association of the Val66Met polymorphism with an increase of susceptibility to develop mood disorders [200–202]. Finally, a recent paper showed that subjects with the Met allele of the BDNF gene are more likely to develop depression [134].

A disruption in serotonin signaling in the brain is also believed to be involved in the pathophysiology of depression. Changes in synaptic serotonin levels and receptor levels are coupled with altered synaptic plasticity and neurogenesis [203,204]. It has been proposed that chronic treatment with conventional antidepressants, such as SSRIs, but not acute administration increases neurogenesis [205–207] and selective SSRIs might reactivate serotonin’s ability to mediate developmental plasticity. BDNF acts as a modulator of the 5-HT system and vice versa, acting as the link between the antidepressant drug and the neuroplastic changes. Close molecular connections between serotonin receptors and neurotrophic proteins such as BDNF and intracellular signaling cascades are responsible for cytoskeletal rearrangement [169,208–211]. Thus, dysregulation in 5-HT–BDNF interaction may be responsible for the development of neuropsychiatric and behavioral abnormalities [212].

Understanding the function of the members of the BDNF system in response to the challenges of the environment and the interaction with different 5-HT receptors in health and disease will lead to new classes of drugs that could be used in therapy for psychiatric and neurodegenerative disorders.

3.5. Effect of Antidepressant Therapies on Plasticity BDNF-Mediated

3.5.1. BDNF and Antidepressant Treatments

Multiple lines of evidence suggest that antidepressant treatments increase BDNF mRNA and protein levels in the cerebral cortex and hippocampus (for review see [213,214]). This increase is partly due to a reduction of histone acetylation in the BDNF promoter regions. The involvement of BDNF in the efficacy of antidepressant treatments has mainly been demonstrated in rodent models. It has been demonstrated that all pharmacological classes of clinical antidepressants increase TrkB autophosphorylation and signaling in the hippocampus and forebrain, effects observed within hours
after the administration of the drug [203,215]. Similar results in BDNF mRNA and TrkB phosphorylation have been observed after acute treatment with ketamine [216–219]. In rodents, injection of BDNF in the hippocampus reduces depression-like behavior [220], in contrast injection of BDNF into the nucleus accumbens or ventral tegmental area promotes depressive effects [221], demonstrating the network-dependent effect of BDNF in mood regulation. Interestingly, conditional knockout of BDNF in forebrain regions increases depressive behavior in females, but not in male mice [222], and blocks the effects of antidepressants desipramine or ketamine [216,223]. Similarly, conditional deletion of TrkB in dentate gyrus or inhibition of TrkB signaling by a dominant-negative TrkB receptor blocks the effects of antidepressants [224,225]. In addition, mice with Val66Met polymorphism are insensitive to antidepressants [226]. Recent evidence demonstrates that the antidepressant effects of GLYX-13, a novel glutamatergic compound that acts as an NMDA modulator with glycine-like partial agonist properties, are blocked by intra-medial prefrontal cortex infusion of an anti-BDNF antibody or in mice with a knock-in of the BDNF Val66Met allele. Pharmacological inhibition of BDNF-TrkB signaling or L-type voltage-dependent Ca\(^{2+}\) channels (VDCCs) blocks the antidepressant behavioral actions of GLYX-13 [227].

Taken together, these data suggest that BDNF serves as a transducer, acting as the link between the antidepressant drug and the neuroplastic changes that result in the improvement of depressive symptoms.

3.5.2. Beneficial Effects of Exercise on Plasticity: The Role of BDNF

Several lines of evidence suggest that exercise has beneficial effects on plasticity and BDNF could be a link between plasticity and physical activity. Although it has been proven that exercise in MDD patients reduced depressive symptoms [228–230], neuroplasticity per se has not yet been monitored in these patients. However, voluntary physical exercise, like an enriched environment, increases expression of BDNF in the hippocampus [8], as well as hippocampal neurogenesis [9] and this could improve brain function by enhancing plasticity, cognition, learning, and memory [12–14]. Physical exercise is one particularly effective strategy for increasing circulating levels of BDNF [10,11]. It has repeatedly been demonstrated that an acute bout of aerobic exercise transiently increases both serum and plasma BDNF in an intensity-dependent manner [10,11]. Exercise increases the release of BDNF from the human brain [231,232] suggesting that exercise also mediates central BDNF production in humans. It has been suggested that miR-34a potentially can also mediate changes in BDNF expression and may reflect the decrease in performance after overtraining [233].

Multiple studies suggest that BDNF has a dominant role in mediating the effects of physical activity on cognitive changes [234]. It has been shown that three months of aerobic exercise training increases hippocampal volume in healthy individuals and in patients with schizophrenia by 12% and 16%, respectively [235]. The question whether exercise regulates muscle-derived circulating factors that can pass through the blood–brain barrier and stimulate BDNF production in the brain remains unclear. In 2016, Moon et al. show that the myokine cathepsin B (Ctsb) might be involved in mediating the exercise-induced improvement in hippocampal neurogenesis, memory, and learning [236]. Mice lacking Ctsb showed depression-like symptoms when they were forced to swim [236].

Other papers have demonstrated that exercise induces upregulation in skeletal muscle of PGC1\(\alpha\), a transcriptional co-activator of mitochondrial biogenesis and oxidative metabolism in brown adipose tissue and muscle. In muscle, the increase of PGC1\(\alpha\) expression stimulates an upregulation of FNDC5, a membrane protein that is cleaved and secreted into the circulation as the myokine irisin [237]. FNDC5 cross the blood–brain barrier inducing BDNF expression in the hippocampus, in this way BDNF plays a role in neurogenesis and reward-related learning and motivation [238]. Current research has also shown that high intensity exercise increases peripheral lactate and BDNF levels; at the same time lactate infusion at rest can increase peripheral and central BDNF levels. Lactate and BDNF can induce neuroplasticity [239]. In addition, acute elevation of BDNF did not compensate for hypoxia-induced cognition impairment [240].
The identification of exercise-related factors that have a direct or indirect effect on brain function has the potential to highlight novel therapeutic targets for neurodegenerative diseases.

4. The Protective Role of BDNF on Neurodegeneration

Neurodegenerative diseases comprise a wide range of neurological diseases such as AD, PD, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), characterized by the deterioration and then the death of selective nuclei of neurons in the brain or the spinal cord. They are chronic and progressive diseases, currently incurable and highly debilitating, causing a tremendous emotional and economic burden on patients, their families, and society. AD, the most frequent among neurodegenerative diseases, accounts for about 70% of dementia cases all over the world; that is about 35 million people. It is estimated to cost more than 480 billion euros each year throughout the world (Sources: OMS, EBC (European Brain Council)). Currently, no pharmacological treatment is available to cure or even significantly slow down the course of neurodegenerative diseases. For these reasons, experimental findings showing that physical exercise, exposure to an enriched environment, metabolic changes and nutritional and/or cognitive intervention, may exert a protective role on neurodegeneration either by delaying the onset and/or curbing the course of the disease, raise hope that these new tools might be useful also in clinical practice. BDNF appears to be crucial or, in some cases even essential, to mediate the neuroprotective effects of the above-mentioned environmental stimuli (Figure 3). In particular, as discussed above, it is well established that BDNF accounts for the hippocampal adult neurogenesis, which, in turn, can be stimulated by a number of conditions such as physical exercise, enriched environment, hormonal balance (i.e., steroid hormones such as cortisol and testosterone) and nutritional intervention (i.e., fasting, low-calorie intake, low-carb diet, selective nutrient intakes), capable of increasing the BDNF level [241].

**Figure 3.** The molecular mechanisms mediated by BDNF involved in depression, Alzheimer’s disease, and glioma. External stimuli (stress, maternal deprivation, or lack of activity) causing epigenetic regulation processes can induce a reduction in BDNF expression level and in neuronal activity.
This results in atrophy, neuronal death, and cognitive decline, which may contribute to depression or Alzheimer’s disease. In these pathologies the BDNF/TrkB signaling, which activates the downstream Akt and ERK signaling, is altered. Thus, such alterations cause an impairment of CREB signaling resulting in BDNF downregulation. The alteration of phosphorylation (P) inhibits (red X) the transcriptional machinery. In the mouse brain, environmental enrichment induces an increase of BDNF. BDNF, binding the truncated form of TrkB receptor (TrkB.T1), signals directly to the Rho protein dissociation inhibitor (GDI). The latter detaches from TrkB.T1 and binds to the small G protein RhoA, leading to an inhibition of glioma cell migration. BDNF stimulates also indirectly the production of IL-15 in microglia, which in turn stimulates the natural killer cells to produce IFN-γ. IFN-γ contributes to reducing glioma growth.

4.1. The Protective Role of BDNF on Alzheimer’s Disease

A reduced level of BDNF has been found in patients affected by neurodegenerative diseases such as Parkinson’s, Huntington’s and Alzheimer’s disease as well as in mild cognitive impairment, the latter being a prodromal stage of AD, characterized by a slight decline of cognitive abilities including memory, thinking and judging skills [242–245]. In some instances, the levels of BDNF even correlate with the severity of the diseases, pointing towards a pathogenetic link between BDNF and AD [246]. Although there are some papers reporting an increase of BDNF in serum or in the post-mortem brain, this might be due either to compensatory mechanisms or its release from immune cells or pharmacological treatments known to raise BDNF (i.e., antidepressants) [241].

Recently, a very complex study explored the role of physical activity in a genetic mouse model of AD. This study provided the most compelling evidence of the relationship between physical activity, adult hippocampal neurogenesis, BDNF, and AD. This study elegantly confirms that adult hippocampal neurogenesis plays a pivotal role in brain resilience to AD. They manipulated with pharmacological and genetic tool neurogenesis as well as BDNF, clearly showing that physical exercise needs neurogenesis to protect the brain from AD and that BDNF is essential for such a protection. In addition, it provides evidence that adult hippocampal neurogenesis can counteract AD memory impairment, only in combination with BDNF, whereas if neurogenesis is experimentally blocked, BDNF does not exert beneficial effects. Finally, pharmacological increase of BDNF further ameliorates AD pathology [247]. Thus, agents that promote both BDNF signaling and neurogenesis might be the key to preventing or curing AD. As far as metabolism is concerned, it has been shown that intermittent fasting, by causing a transition from utilization of carbohydrate and glucose to a fatty acid and ketones source of energy (refer to as “G-K shift”) generates a number of beneficial cognitive, metabolic, and cardiovagal effects. BDNF is increased upon intermittent fasting and mediates at least part of these effects. Its increase is stimulated by the ketone body, β-hydroxybutyrate that inhibits histone deacetylases that repress BDNF promoters [248]. Recently, the role of BDNF and neuroprotection in the context of metabolism and fasting has been nicely reviewed by Mattson et al. [6].

4.2. BDNF and Ras-ERK-CREB Signaling in Alzheimer’s Disease

BDNF, as also discussed above, causes the activation of the Ras-ERK signaling cascade leading to the phosphorylation of CREB. Such a pathway exerts a well-known trophic and protective role on neuronal cells both in vitro and in vivo in a variety of neurodegenerative models, including AD, PD, and Huntington’s diseases. Nevertheless, it has become clear that the Ras-ERK pathway may also foster neurodegeneration or hamper the action of neurotrophic factors when activated by noxious stimuli as occurs for instance in PD and AD [249]. In particular, it has been shown in a number of different cellular models such as primary cortical rat neurons, rat B103 neuroblastoma cells, and A1 mouse mesencephalic cells, that APP and/or Aβ42 oligomer induces the activation of Ras-ERK and GSK-3 signaling, that, in turn, causes hyperphosphorylation of tau and APP at Thr668. The involvement of these molecular events in the pathogenesis AD is corroborated by the finding that activation of Ras-ERK and GSK-3 correlates with Aβ levels in the brain of AD patients [250,251]. Aberrant stimulation of Ras-ERK signaling forces neurons to enter the cell cycle as shown by the expression and nuclear accumulation of cyclin D1 and the subsequent G1/S progression. Since neurons lack functional cell
cycle machinery, these events lead to cell death (i.e., mitotic catastrophe) instead of cell division. Interestingly, as clearly shown in the mouse model of familial AD APPswe/PS1ΔE9 mice, although ERK phosphorylation is enhanced compared to the wild type counterpart, it does not result in normal CREB phosphorylation. The impairment in CREB signaling parallels to impairment in a number of cognitive tests [252]. Therefore, in AD, BDNF downregulation is mediated by the impairment of CREB signaling caused by amyloid β [253] (Figure 3).

5. BDNF and Brain Cancer: An Unexpected Role. An Oncogene or a Tumor Suppressor?

The role of BDNF and its cognate receptor TrkB in cancer, including brain cancer, has been recognized for a long time [254]. In many types of cancers, BDNF and/or TrkB have been found expressed or in some cases over-expressed [255]. This is not surprising since growth factors, including neurotrophic factors, and their tyrosine kinase receptors have long been involved in tumors with different cell-dependent mechanisms, fostering proliferation, enhancing anti-apoptotic signaling, and making cells unresponsive to anti-proliferative stimuli [256]. The direct oncogenic activity of TrkB might also be due to the crosstalk with EGF receptors that together with its ligand is well-known to promote cell transformation. BDNF administration not only does phosphorylate TrkB but also EGFR [257]. In line with these observations, it has been recently shown that BDNF produced by glioblastoma (GBM) differentiated cells acts on GBM stem cells, fostering their growth through paracrine signaling [258].

However, recently another study showed that exposing mice to an enriched environment is able to decrease the growth of intracranial glioma, decreasing proliferation and invasion, and improving overall survival. Such an effect is achieved by means of both indirect and direct mechanisms. The former acts via natural killer cells of the innate immune system, whereas the latter utilizes BDNF stimulation of its truncated receptor TrkB.T1 on glioma cancer cells. BDNF binding the TrkB.T1 receptor signals to the Rho protein dissociation inhibitor (RhoGDI), the latter detaches from TrkB.T1 and binds to the small G protein RhoA, leading to its inhibition. The authors found that an enriched environment causes the synthesis of IL-15 and BDNF. When mice bearing the glioma and not housed in enriched environments were infused with BDNF, they reduced tumor size and macrophage infiltration. Thus, showing that at least in part, BDNF accounts for the oncolytic effect elicited by the enriched environment [259]. In a more recent study, the same group delved deeper into the mechanisms, finding that enriched environment changes glioma-associated myeloid cells. BDNF plays a central role by stimulating the production of IL-15 in microglia, which in turn stimulates the natural killer cells to produce IFN-γ. Natural killer cells were responsible for the switch to an oncolytic environment [260] (Figure 3).

Taken together, a scenario emerges where BDNF, acting on different cells is able to reorganize the brain microenvironment in such a way that it becomes resilient to neurodegeneration or oncolytic for tumors. In this regard, although supported by much more preliminary data, it seems that also other compounds might share these properties [261,262].

6. Conclusions

In this review, we discussed the role of BDNF in neurogenesis, differentiation, survival, synaptic plasticity, and transmission to reorganize the brain microenvironment. All BDNF gene products, such as proBDNF, mature BDNF, and even the isolated proBDNF domain, are known to exert functional activity. One of the most important features of BDNF is that it can act as a local, paracrine and/or autocrine factor, on both pre-synaptic and post-synaptic target sites. Here, we presented the contribution of altered BDNF signaling in the pathophysiology of brain diseases, including mental disorders (i.e., depression), neurodegenerative diseases, (i.e., Alzheimer’s disease), and brain tumor (i.e., glioblastoma). BDNF is one of the best-studied synaptic molecules that efficiently modify synaptic strength and it can act as a mediator, modulator, or instructor of synaptic plasticity. In neurons, the cellular processes that regulate the amount of both BDNF mRNA and protein, the changes in the efficiency of secretion, and transport of BDNF protein may affect synaptic function and cell survival. BDNF is one of the most inspiring
molecules to better understand the disadvantageous synaptic learning underlying the etiology of depression, accompanied by the decline in the rate of adult neurogenesis and in spine densities. Furthermore, BDNF appears to exert a potent role in neuroprotection and/or brain regeneration by modulating signaling pathways such Ras-ERK-CREB, thus rendering neuronal cells resilient to neurodegeneration. Finally, BDNF appears to be crucial in the pathogenesis and development of brain tumors such as glioblastoma by reorganizing its microenvironment. Thus, understanding the physiologic and pathologic BDNF signaling and finding tools to modulate its expression (mRNA and/or protein) is a prerequisite for a potential BDNF-based therapy.

Author Contributions: Original draft preparation, writing and editing, L.C.-D., L.S.; original draft preparation, writing and review, F.V. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by program VALERE: VAnviteLli pEr la RicErca to L.C.D.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AD Alzheimer’s Disease
API Activator Protein 1
BCL2 B-cell lymphoma 2
BDNF Brain-Derived Neurotrophic Factor
BHHLB2 Helix-loop-helix protein
CaMK Ca\textsuperscript{2+}/calmodulin-dependent protein kinase
cAMP/CRE Cyclic adenosine monophosphate calcium response element
CaREs Calcium-responsive elements
CREB CREB
Ctsb Myokine cathepsin B
CUMS Chronic Unpredicted Mild Stress model
DAG 1,2-diacylglycerol
ERK Extracellular signal-regulated kinase
GTP-ases guanosine triphosphate hydrolases
JNK c-Jun amino terminal kinase
IKK Multi-subunit IkB kinase
IkB Inhibitor of IkB
L-VGCC L-type voltage gated calcium channel
LTP Long-Term Potentiation
MAPK Mitogen-activated protein kinase
MDD Major depressive disorder
Met Methionine
miRNAs microRNAs
MMP Matrix Metalloproteases
MPP 1-methyl-4-phenylpyridinium
NF-\textit{k}B Nuclear Factor kappa-light-chain-enhancer of activated B cells
NM\textit{A} N-Methyl-D-Aspartate
NRAGE Neurotrophin receptor-interacting MAGE homologue
NRIF Neurotrophin receptor interacting factor
PD Parkinson’s disease
p75NTR p75 neurotrophin receptor
PI3K Phosphoinositide 3-kinases
PKC Protein kinase C
PLC Phospholipase C
Rho Ras homolog
ROCK Rho-associated protein kinase
SIRT1 Sirtuin 1
SNPs Polymorphism
SSRIs Serotonin reuptake inhibitor
TRAF6 Tumor necrosis factor receptor associated factor 6
TrkB Tropomyosin receptor kinase B
Val Valine
VDCCs L-type voltage-dependent Ca$^{2+}$ channels
Vps10p Vacuolar protein sorting 10 protein

References

1. Andreska, T.; Aufmkolk, S.; Sauer, M.; Blum, R. High abundance of BDNF within glutamatergic presynapses of cultured hippocampal neurons. *Front. Cell Neurosci.* 2014, 8, 107. [CrossRef]

2. Clarke, L.E.; Liddelow, S.A.; Chakraborty, C.; Münch, A.E.; Heiman, M.; Barres, B.A. Normal aging induces A1-like astrocyte reactivity. *Proc. Natl. Acad. Sci. USA* 2018, 115, E1896–E1905. [CrossRef]

3. Parkhurst, C.N.; Yang, G.; Ninan, I.; Savas, J.N.; Yates, J.R.; Lafaille, J.J.; Hempstead, B.L.; Littman, D.R.; Gan, W.B. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell* 2013, 155, 1596–1609. [CrossRef]

4. Bartkowska, K.; Paquin, A.; Gauthier, A.S.; Kaplan, D.R.; Miller, F.D. Trk signaling regulates neural precursor cell proliferation and differentiation during cortical development. *Development* 2007, 134, 4369–4380. [CrossRef]

5. Vilar, M.; Mira, H. Regulation of Neurogenesis by Neurotrophins during Adulthood: Expected and Unexpected Roles. *Front. Neurosci.* 2016, 10, 26. [CrossRef]

6. Mattson, M.P.; Moehl, K.; Ghena, N.; Schmaedick, M.; Cheng, A. Intermittent metabolic switching, neuroplasticity and brain health. *Nat. Rev. Neurosci.* 2018, 19, 63–80. [CrossRef]

7. Numakawa, T.; Odaka, H.; Adachi, N. Actions of Brain-Derived Neurotrophin Factor in the Neurogenesis and Neuronal Function, and Its Involvement in the Pathophysiology of Brain Diseases. *Int. J. Mol. Sci.* 2018, 19, 3650. [CrossRef]

8. Loprinzi, P.D.; Day, S.; Deming, R. Acute Exercise Intensity and Memory Function: Evaluation of the Transient Hypofrontality Hypothesis. *Medicina (Kaunas)* 2019, 55, 445. [CrossRef]

9. Fabel, K.; Wolf, S.A.; Ehninger, D.; Babu, H.; Leal-Galicia, P.; Kempermann, G. Additive effects of physical exercise and environmental enrichment on adult hippocampal neurogenesis in mice. *Front. Neurosci.* 2009, 3, 50. [CrossRef]

10. Knaepen, K.; Goekint, M.; Heyman, E.M.; Meeseusen, R. Neuroplasticity-exercise-induced response of peripheral brain-derived neurotrophic factor: A systematic review of experimental studies in human subjects. *Sports Med.* 2010, 40, 765–801. [CrossRef]

11. Szuhany, K.L.; Bugatti, M.; Otto, M.W. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. *J. Psychiatr. Res.* 2015, 60, 56–64. [CrossRef] [PubMed]

12. van Praag, H.; Shubert, T.; Zhao, C.; Gage, F.H. Exercise enhances learning and hippocampal neurogenesis in aged mice. *J. Neurosci.* 2005, 25, 8680–8685. [CrossRef] [PubMed]

13. Tuon, T.; Souza, P.S.; Santos, M.E.; Pereira, F.T.; Pedroso, G.S.; Luciano, T.F.; De Souza, C.T.; Dutra, R.C.; Silveira, P.C.; Pinho, R.A. Physical Training Regulates Mitochondrial Parameters and Neuroinflammatory Mechanisms in an Experimental Model of Parkinson’s Disease. *Oxid. Med. Cell. Longev.* 2015, 2015, 261809. [CrossRef] [PubMed]

14. Vilela, T.C.; Muller, A.P.; Damiani, A.P.; Macan, T.P.; da Silva, S.; Canteiro, P.B.; de Sena Casagrande, A.; Pedroso, G.D.S.; Nesi, R.T.; de Andrade, V.M.; et al. Strength and Aerobic Exercises Improve Spatial Memory in Aging Rats Through Stimulating Distinct Neuroplasticity Mechanisms. *Mol. Neurobiol.* 2017, 54, 7928–7937. [CrossRef]

15. Itami, C.; Kimura, F.; Kohno, T.; Matsuoka, M.; Ichikawa, M.; Tsumoto, T.; Nakamura, S. Brain-derived neurotrophic factor-dependent unmasking of “silent” synapses in the developing mouse barrel cortex. *Proc. Natl. Acad. Sci. USA* 2003, 100, 13069–13074. [CrossRef]
16. Edelmann, E.; Lessmann, V.; Brigadski, T. Pre-and postsynaptic twists in BDNF secretion and action in synaptic plasticity. *Neuropharmacology* 2014, 76 Pt C, 610–627. [CrossRef]

17. Nakahashi, T.; Fujimura, H.; Altar, C.A.; Li, J.; Kambayashi, J.; Tandon, N.N.; Sun, B. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. *FEBS Lett.* 2000, 470, 113–117. [CrossRef]

18. Wang, H.; Ward, N.; Boswell, M.; Katz, D.M. Secretion of brain-derived neurotrophic factor from brain microvascular endothelial cells. *Eur. J. Neurosci.* 2006, 23, 1665–1670. [CrossRef]

19. Pius-Sadowska, E.; Machalinski, B. BDNF-A key player in cardiovascular system. *J. Mol. Cell. Cardiol.* 2017, 110, 54–60. [CrossRef]

20. Anders, Q.S.; Ferreira, L.V.B.; Rodrigues, L.C.M.; Nakamura-Palacios, E.M. BDNF mRNA Expression in Leukocytes and Frontal Cortex Function in Drug Use Disorder. *Front. Psychiatry* 2020, 11, 469. [CrossRef]

21. Chacón-Fernández, P.; Säuberli, K.; Colzani, M.; Moreau, T.; Ghevaert, C.; Barde, Y.A. Brain-derived Neurotrophic Factor in Megakaryocytes. *J. Biol. Chem.* 2016, 291, 9872–9881. [CrossRef] [PubMed]

22. Amadio, P.; Sandrini, L.; Ieraci, A.; Tremoli, E.; Barbieri, S.S. E

23. Meek, T.H.; Wisse, B.E.; Thaler, J.P.; Guyenet, S.J.; Matsen, M.E.; Fischer, J.D.; Taborsky, G.J.; Schwartz, M.W.; Morton, G.J. BDNF action in the brain attenuates diabetic hyperglycemia via insulin-independent inhibition of hepatic glucose production. *Diabetes* 2013, 62, 1512–1518. [CrossRef] [PubMed]

24. Marosi, K.; Mattsson, M.P. BDNF mediates adaptive brain and body responses to energetic challenges. *Trends Endocrinol. Metab.* 2014, 25, 89–98. [CrossRef] [PubMed]

25. Delezie, J.; Weihrauch, M.; Maier, G.; Tejero, R.; Ham, D.J.; Gill, J.F.; Karrer-Cardel, B.; Ruegg, M.A.; Tabares, L.; Handschin, C. BDNF is a mediator of glycolytic fiber-type specification in mouse skeletal muscle. *Proc. Natl. Acad. Sci. USA* 2019, 116, 16111–16120. [CrossRef]

26. Tettamanti, G.; Cattaneo, A.G.; Gornati, R.; de Eguileor, M.; Bernardini, G.; Binelli, G. Phylogenesis of brain-derived neurotrophic factor (BDNF) in vertebrates. *Gene* 2010, 450, 85–93. [CrossRef]

27. Metsis, M.; Timmusk, T.; Arenas, E.; Persson, H. Differential usage of multiple brain-derived neurotrophic factor promoters in the rat brain following neuronal activation. *Proc. Natl. Acad. Sci. USA* 1993, 90, 8802–8806. [CrossRef]

28. Timmusk, T.; Lendahl, U.; Funakoshi, H.; Arenas, E.; Persson, H.; Metsis, M. Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice. *J. Cell Biol.* 1995, 128, 185–199. [CrossRef]

29. Timmusk, T.; Palm, K.; Metsis, M.; Reintam, T.; Paelme, V.; Saarma, M.; Persson, H. Multiple promoters direct tissue-specific expression of the rat BDNF gene. *Neuron* 1993, 10, 475–489. [CrossRef]

30. Volpicelli, F.; Caiazzo, M.; Greco, D.; Consales, C.; Leone, L.; Perrone-Capano, C.; Colucci D’Amato, L.; di Porzio, U. Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. *J. Neurochem.* 2007, 102, 441–453. [CrossRef] [PubMed]

31. Vashishta, A.; Habas, A.; Prunusild, P.; Zheng, J.J.; Timmusk, T.; Hetman, M. Nuclear factor of activated T-cells isoform c4 (NFATc4) as a mediator of antiapoptotic transcription in NMDA receptor-stimulated cortical neurons. *J. Neurosci.* 2009, 29, 15331–15340. [CrossRef]

32. Paoletti, P.; Bellone, C.; Zhou, Q. NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease. *Nat. Rev. Neurosci.* 2013, 14, 383–400. [CrossRef] [PubMed]

33. Simms, B.A.; Zamponi, G.W. Neuronal voltage-gated calcium channels: Structure, function, and dysfunction. *Neuron* 2014, 82, 24–45. [CrossRef]

34. Tao, X.; Finkbeiner, S.; Arnold, D.B.; Shaywitz, A.J.; Greenberg, M.E. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. *Neuron* 1998, 20, 709–726. [CrossRef]

35. Tabuchi, A.; Sakaya, H.; Kisukeda, T.; Fushiki, H.; Tsuda, M. Involvement of an upstream stimulatory factor as well as cAMP-responsive element-binding protein in the activation of brain-derived neurotrophic factor gene promoter *I. J. Biol. Chem.* 2002, 277, 35920–35931. [CrossRef]
39. Pruunsild, P.; Sepp, M.; Orav, E.; Koppel, I.; Timmusk, T. Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. *J. Neurosci.* 2011, 31, 3295–3300. [CrossRef]

40. Tao, X.; West, A.E.; Chen, W.G.; Corfas, G.; Greenberg, M.E. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. *Neuron* 2002, 33, 383–395. [CrossRef]

41. Zheng, F.; Wang, H. NMDA-mediated and self-induced bdnf exon IV transcriptions are differentially regulated in cultured cortical neurons. *Neurochem. Int.* 2009, 54, 385–392. [CrossRef] [PubMed]

42. Lipsky, R.H.; Xu, K.; Zhu, D.; Kelly, C.; Terhakopian, A.; Novelli, A.; Marini, A.M. Nuclear factor kappaB is a critical determinant in N-methyl-D-aspartate receptor-mediated neuroprotection. *J. Neurochem.* 2001, 78, 254–264. [CrossRef] [PubMed]

43. Zheng, F.; Zhou, X.; Moon, C.; Wang, H. Regulation of brain-derived neurotrophic factor expression in neurons. *Int. J. Physiol. Pathophysiol. Pharmacol.* 2012, 4, 188–200. [PubMed]

44. Jiang, X.; Tian, F.; Du, Y.; Copeland, N.G.; Jenkins, N.A.; Tessarollo, L.; Wu, X.; Pan, H.; Hu, X.Z.; Xu, K.; et al. BHLHB2 controls Bdnf promoter 4 activity and neuronal excitability. *J. Neurosci.* 2008, 28, 1118–1130. [CrossRef]

45. Sakata, K.; Woot, N.H.; Martinowich, K.; Greene, J.S.; Schloesser, R.J.; Shen, L.; Lu, B. Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. *Proc. Natl. Acad. Sci. USA* 2009, 106, 5942–5947. [CrossRef]

46. Keller, S.; Sarchiapone, M.; Zarrilli, F.; Videtic, A.; Ferraro, A.; Carli, V.; Sacchetti, S.; Lembo, F.; Angiolillo, A.; Jovanovic, N.; et al. Increased BDNF promoter methylation in the Wernicke area of suicide subjects. *Arch. Gen. Psychiatry* 2010, 67, 258–267. [CrossRef]

47. Tadić, A.; Müller-Engling, L.; Schlicht, K.; Dreimüller, N.; Kleimann, A.; Lieb, K.; Frieling, H. Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. *Mol. Psychiatry* 2014, 19, 281–283. [CrossRef]

48. Lieb, K.; Dreimüller, N.; Wagner, S.; Schlicht, K.; Falter, T.; Neyazi, A.; Müller-Engling, L.; Bleich, S.; Tadić, A.; Frieling, H. BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response. *Front. Psychiatry* 2018, 9, 511. [CrossRef]

49. Sakata, K.; Duke, S.M. Lack of BDNF expression through promoter IV disturbs expression of monoamine genes in the frontal cortex and hippocampus. *Neuroscience* 2014, 260, 265–275. [CrossRef]

50. Hill, J.L.; Hardy, N.F.; Jimenez, D.V.; Maynard, K.R.; Kardian, A.S.; Pollock, C.J.; Schloesser, R.J.; Martinowich, K. Loss of promoter IV-driven BDNF expression impacts oscillatory activity during sleep, sensory information processing and fear regulation. *Transl. Psychiatry* 2016, 6, e873. [CrossRef]

51. Volpicelli, F.; Speranza, L.; Pulcrano, S.; De Gregorio, R.; Crispino, M.; De Sanctis, C.; Leopoldo, M.; Lacivita, E.; di Porzio, U.; Bellenchii, G.C.; et al. The microRNA-29a Modulates Serotonin 5-HT7 Receptor Expression and Its Effects on Hippocampal Neuronal Morphology. *Mol. Neurobiol.* 2019, 56, 8617–8627. [CrossRef] [PubMed]

52. De Gregorio, R.; Pulcrano, S.; De Sanctis, C.; Volpicelli, F.; Guatteo, E.; von Oerthel, L.; Lataglia, E.C.; Esposito, R.; Piscitelli, R.M.; Perrone-Capano, C.; et al. miR-34b/c Regulates Wnt1 and Enhances Mesencephalic Dopaminergic Neuron Differentiation. *Stem Cell Rep.* 2018, 10, 1237–1250. [CrossRef] [PubMed]

53. McNell, E.; Van Vactor, D. MicroRNAs shape the neuronal landscape. *Neuron* 2012, 75, 363–379. [CrossRef] [PubMed]

54. Keifer, J.; Zheng, Z.; Ambigapathy, G. A MicroRNA-BDNF Negative Feedback Signaling Loop in Brain: Implications for Alzheimer’s Disease. *Microrna* 2015, 4, 101–108. [CrossRef] [PubMed]

55. Khani-Habibabadi, F.; Askari, S.; Zahiri, J.; Javan, M.; Behmanesh, M. Novel BDNF-regulatory microRNAs in neurodegenerative disorders pathogenesis: An in silico study. *Comput. Biol. Chem.* 2019, 83, 107153. [CrossRef] [PubMed]

56. Schratt, G.M.; Taebing, F.; Nigh, E.A.; Kane, C.G.; Sabatini, M.E.; Kiebler, M.; Greenberg, M.E. A brain-specific microRNA regulates dendritic spine development. *Nature* 2006, 439, 283–289. [CrossRef]

57. Baby, N.; Alagappan, N.; Dheen, S.T.; Sajikumar, S. MicroRNA-134-5p inhibition rescues long-term excitability and synaptic tagging/capture in an Aβ(1-42)-induced model of Alzheimer’s disease. *Aging Cell* 2020, 19, e13046. [CrossRef]
58. Zhao, X.; Shu, F.; Wang, X.; Wang, F.; Wu, L.; Li, L.; Lv, H. Inhibition of microRNA-375 ameliorated Barde, Y.A.; Edgar, D.; Thoenen, H. Purification of a new neurotrophic factor from mammalian brain. Behav. Brain Res. 2018, 349, 1–7. [CrossRef]
59. Shen, J.; Xu, L.; Qu, C.; Sun, H.; Zhang. J. Resveratrol prevents cognitive deficits induced by chronic unpredictable mild stress: Sirt1/miR-134 signalling pathway regulates CREB/BDNF expression in hippocampus in vivo and in vitro. Neurotox. Res. 2020, 37, 171–182. [CrossRef] [PubMed]
60. Xin, C.; Xia, J.; Liu, Y.; Zhang. Y. MicroRNA-202-3p Targets Brain-Derived Neurotrophic Factor and Is Involved in Depression-Like Behaviors. Neuropsychiatr. Dis. Treat. 2020, 16, 1073–1083. [CrossRef]
61. Yang, C.R.; Zhang, X.Y.; Liu, Y.; Du, J.Y.; Liang, R.; Yu, M.; Zhang, F.Q.; Mu, X.F.; Li, F.; Zhou, L.; et al. Antidepressant Drugs Correct the Imbalance Between proBDNF/p75NTR/Sortilin and Mature BDNF/TrkB in the Brain of Mice with Chronic Stress. [CrossRef] [PubMed]
62. You, Y.H.; Qin, Z.Q.; Zhang, H.L.; Yuan, Z.H.; Yu, X. MicroRNA-153 promotes brain-derived neurotrophic factor and hippocampal neuron proliferation to alleviate autism symptoms through inhibition of JAK-STAT pathway by LEPR. Biosci. Rep. 2019, 39. [CrossRef]
63. Rostamian Delavar, M.; Baghi, M.; Safaeinejad, Z.; Kiani-Esfahani, A.; Ghaedi, K.; Nasr-Esfahani, M.H. Differential expression of miR-34a, miR-141, and miR-9 in MPP′-treated differentiated PC12 cells as a model of Parkinson’s disease. Gene 2018, 662, 54–65. [CrossRef] [PubMed]
64. Zhao, X.; Shu, F.; Wang, X.; Wang, F.; Wu, L.; Li, L.; Lv, H. Inhibition of microRNA-375 ameliorated ketamine-induced neurotoxicity in human embryonic stem cell derived neurons. Eur. J. Pharmacol. 2019, 844, 56–64. [CrossRef] [PubMed]
65. Jiang, J.D.; Zheng, X.C.; Huang, F.Y.; Gao, F.; You, M.Z.; Zheng, T. MicroRNA-107 regulates anesthesia-induced neural injury in embryonic stem cell derived neurons. ILJIBM Life 2019, 71, 20–27. [CrossRef] [PubMed]
66. Barde, Y.A.; Edgar, D.; Thoenen, H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982, 1, 549–553. [CrossRef]
67. Foltran, R.B.; Diaz, S.L. BDNF isoforms: A round trip ticket between neurogenesis and serotonin? J. Neurochem. 2016, 138, 204–221. [CrossRef]
68. Mizu, T.; Ishikawa, Y.; Kumanogoh, H.; Kojima, M. Neurobiological actions by three distinct subtypes of brain-derived neurotrophic factor: Multi-ligand model of growth factor signaling. Pharmaco. Res. 2016, 105, 93–98. [CrossRef]
69. Lu, J.; Wu, Y.; Sousa, N.; Almeida, O.F. SMAD pathway mediation of BDNF and TGF beta 2 regulation of proliferation and differentiation of hippocampal granule neurons. Development 2005, 132, 3231–3242. [CrossRef]
70. Kowiariski, P.; Lietzau, G.; Czuba, E.; Waśkow, M.; Steliga, A.; Moryś, J. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cell Mol. Neurobiol. 2018, 38, 579–593. [CrossRef]
71. Pang, P.T.; Teng, H.K.; Zaitsev, E.; Woo, N.T.; Sakata, K.; Zhen, S.; Teng, K.K.; Yung, W.H.; Hempstead, B.L.; Lu, B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306, 487–491. [CrossRef]
72. Mizoguchi, H.; Nakade, J.; Tachibana, M.; Ibi, D.; Someya, E.; Koike, H.; Kamei, H.; Nabeshima, T.; Itohara, S.; Takuma, K.; et al. Matrix metalloproteinase-9 contributes to kindled seizure development in pentyleneetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus. J. Neurosci. 2011, 31, 12963–12971. [CrossRef]
73. Vafadari, B.; Salamian, A.; Kaczmarek, L. MMP-9 in translation: From molecule to brain physiology, pathology, and therapy. J. Neurochem. 2016, 139 (Suppl. S2), 91–114. [CrossRef]
74. Mowl, S.J.; Farhadì, H.F.; Pareek, S.; Atwal, J.K.; Morris, S.J.; Seidah, N.G.; Murphy, R.A. Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophin factor. J. Biol. Chem. 2001, 276, 12660–12666. [CrossRef] [PubMed]
75. Conner, J.M.; Lauterborn, J.C.; Yan, Q.; Gall, C.M.; Varon, S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: Evidence for anterograde axonal transport. J. Neurosci. 1997, 17, 2295–2313. [CrossRef]
76. Dieni, S.; Matsumoto, T.; Dekkers, M.; Rauskolb, S.; Ionescu, M.S.; Deogracias, R.; Gundelfinger, E.D.; Kojima, M.; Nestel, S.; Frotscher, M.; et al. BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. J. Cell Biol. 2012, 196, 775–788. [CrossRef] [PubMed]
77. Yang, J.; Siao, C.J.; Nagappan, G.; Marinic, T.; Jing, D.; McGrath, K.; Chen, Z.Y.; Mark, W.; Tessarollo, L.; Lee, F.S.; et al. Neuronal release of proBDNF Nat. Neurosci. 2009, 12, 113–115. [CrossRef]
78. Yang, J.L.; Lin, Y.T.; Chuang, P.C.; Bohr, V.A.; Mattson, M.P. BDNF and exercise enhance neuronal DNA repair by stimulating CREB-mediated production of apurinic/apyrimidinic endonuclease 1. *Neuromolecular Med.* 2014, 16, 161–174. [CrossRef] [PubMed]

79. Du, J.; Feng, L.; Yang, F.; Lu, B. Activity- and Ca(2+)-dependent modulation of surface expression of brain-derived neurotrophic factor receptors in hippocampal neurons. *J. Cell Biol.* 2000, 150, 1423–1434. [CrossRef] [PubMed]

80. Meyer-Franke, A.; Wilkinson, G.A.; Kruttgen, A.; Hu, M.; Munro, E.; Hanson, M.G.; Reichardt, L.F.; Barres, B.A. Depolarization and cAMP elevation rapidly recruit TrkB to the plasma membrane of CNS neurons. *Neuron* 1998, 21, 681–693. [CrossRef]

81. Deinhardt, K.; Chao, M.V. Shaping neurons: Long and short range effects of mature and proBDNF signalling upon neuronal structure. *Neuropharmacology* 2014, 76 Pt C, 603–609. [CrossRef]

82. Anastasia, A.; Deinhardt, K.; Chao, M.V.; Will, N.E.; Irmady, K.; Lee, F.S.; Hempstead, B.L.; Bracken, C. Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. *Nat. Commun.* 2013, 4, 2490. [CrossRef]

83. Teng, H.K.; Teng, K.K.; Lee, R.; Tevar, S.; Almeida, R.D.; Kermani, P.; Torkin, R.; Chen, Z.Y.; Lee, F.S.; et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. *J. Neurosci.* 2005, 25, 5455–5463. [CrossRef] [PubMed]

84. Roux, P.P.; Colicos, M.A.; Barker, P.A.; Kennedy, T.E. p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure. *J. Neurosci.* 1999, 19, 6887–6896. [CrossRef] [PubMed]

85. Reichardt, L.F. Neurotrophin-regulated signalling pathways. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 2006, 361, 1545–1564. [CrossRef]

86. Kaplan, D.R.; Miller, F.D. Neurotrophin signal transduction in the nervous system. *Curr. Opin. Neurobiol.* 2000, 10, 381–391. [CrossRef]

87. Gonzalez, A.; Moya-Alvarado, G.; Gonzalez-Billaut, C.; Bronfman, F.C. Cellular and molecular mechanisms regulating neuronal growth by brain-derived neurotrophic factor. *Cytoskeleton (Hoboken)* 2016, 73, 612–628. [CrossRef]

88. Huang, E.J.; Reichardt, L.F. Trk receptors: Roles in neuronal signal transduction. *Annu. Rev. Biochem.* 2003, 72, 609–642. [CrossRef]

89. Minichiello, L. TrkB signalling pathways in LTP and learning. *Nat. Rev. Neurosci.* 2009, 10, 850–860. [CrossRef]

90. Patel, A.V.; Krimm, R.F. BDNF is required for the survival of differentiated geniculate ganglion neurons. *Dev. Biol.* 2010, 340, 419–429. [CrossRef]

91. Chen, J.; Shehadah, A.; Pal, A.; Zacharek, A.; Cui, X.; Cui, Y.; Roberts, C.; Lu, M.; Zeitlin, A.; Hariri, R.; et al. Neuropeptidergic effect of human placenta-derived cell treatment of stroke in rats. *Cell Transplant.* 2013, 22, 871–879. [CrossRef] [PubMed]

92. Wu, Y.; Wang, R.; Wang, Y.; Gao, J.; Feng, L.; Yang, Z. Distinct Impacts of Fullerene on Cognitive Functions of Dementia vs. Non-dementia Mice. *Neurotox. Res.* 2019, 36, 736–745. [CrossRef] [PubMed]

93. Gorski, J.A.; Zeiler, S.R.; Tamowski, S.; Jones, K.R. Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. *J. Neurosci.* 2003, 23, 6856–6865. [CrossRef] [PubMed]

94. Kwon, M.; Fernández, J.R.; Zegarek, G.F.; Lo, S.B.; Firestein, B.L. BDNF-promoted increases in proximal dendrites occur via CREB-dependent transcriptional regulation of cypin. *J. Neurosci.* 2011, 31, 9735–9745. [CrossRef]

95. Orefice, L.L.; Waterhouse, E.G.; Partridge, J.G.; Lalchandani, R.R.; Vicini, S.; Xu, B. Distinct roles for somatically and dendritically synthesized brain-derived neurotrophic factor in morphogenesis of dendritic spines. *J. Neurosci.* 2013, 33, 11618–11632. [CrossRef]

96. Zagrebelsky, M.; Tacke, C.; Korte, M. BDNF signaling during the lifetime of dendritic spines. *Cell Tissue Res.* 2020. [CrossRef]

97. Yoshii, A.; Constantine-Paton, M. Postsynaptic localization of PSD-95 is regulated by all three pathways downstream of TrkB signaling. *Front. Synaptic Neurosci.* 2014, 6, 6. [CrossRef]

98. Chen, S.D.; Wu, C.L.; Hwang, W.C.; Yang, D.I. More Insight into BDNF against Neurodegeneration: Anti-Apoptosis, Anti-Oxidation, and Suppression of Autophagy. *Int. J. Mol. Sci.* 2017, 18, 545. [CrossRef]
99. Opazo, P.; Watabe, A.M.; Grant, S.G.; O’Dell, T.J. Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms. *J. Neurosci.* 2003, 23, 3679–3688. [CrossRef]

100. Leal, G.; Bramham, C.R.; Duarte, C.B. BDNF and Hippocampal Synaptic Plasticity. *Vitam. Horm.* 2017, 104, 153–195. [CrossRef]

101. Baydyuk, M.; Xu, B. BDNF signaling and survival of striatal neurons. *Front. Cell. Neurosci.* 2014, 8, 254. [CrossRef]

102. Waterhouse, E.G.; An, J.J.; Orefice, L.L.; Baydyuk, M.; Liao, G.Y.; Lu, B.; Xu, B. BDNF promotes differentiation and maturation of adult-born neurons through GABAergic transmission. *J. Neurosci.* 2012, 32, 14318–14330. [CrossRef] [PubMed]

103. Park, H.; Poo, M.M. Neurotrophin regulation of neural circuit development and function. *Nat. Rev. Neurosci.* 2013, 14, 7–23. [CrossRef]

104. Jaworski, J.; Spangler, S.; Seeburg, D.P.; Hoogenraad, C.C.; Sheng, M. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. *J. Neurosci.* 2005, 25, 11300–11312. [CrossRef] [PubMed]

105. Kumar, V.; Zhang, M.X.; Swank, M.W.; Kunz, J.; Wu, G.Y. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. *J. Neurosci.* 2005, 25, 11288–11299. [CrossRef]

106. Finkbeiner, S.; Tavazoie, S.F.; Maloratsky, A.; Jacobs, K.M.; Harris, K.M.; Greenberg, M.E. CREB: A major mediator of neuronal neurotrophin responses. *Neuron* 1997, 19, 1031–1047. [CrossRef]

107. Xing, J.; Kornhauser, J.M.; Xia, Z.; Thiele, E.A.; Greenberg, M.E. Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. *Mol. Cell. Biol.* 1998, 18, 1946–1955. [CrossRef]

108. Segal, M.; Kreher, U.; Greengberger, V.; Braun, K. Is fragile X mental retardation protein involved in activity-induced plasticity of dendritic spines? *Brain Res.* 2003, 972, 9–15. [CrossRef]

109. Petryshen, T.L.; Sabeti, P.C.; Aldinger, K.A.; Fry, B.; Schaﬀner, S.F.; Waggoner, S.G.; Tahl, A.R.; Sklar, P. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. *Mol. Psychiatry* 2010, 15, 810–815. [CrossRef]

110. Momose, Y.; Murata, M.; Kobayashi, K.; Tachikawa, M.; Nakabayashi, Y.; Kanazawa, I.; Toda, T. Association studies of multiple candidate genes for Parkinson’s disease using single nucleotide polymorphisms. *Ann. Neurol.* 2002, 51, 133–136. [CrossRef]

111. Ventriglia, M.; Bocchio Chiavetto, L.; Benussi, L.; Binetti, G.; Zanetti, O.; Riva, M.A.; Gennarelli, M. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer’s disease. *Mol. Psychiatry* 2002, 7, 136–137. [CrossRef]

112. Egan, M.F.; Kojima, M.; Callicott, J.H.; Goldberg, T.E.; Colachana, B.S.; Bertolino, A.; Zaitsev, E.; Gold, B.; Goldman, D.; Dean, M.; et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 2003, 112, 257–269. [CrossRef]

113. Chen, Z.Y.; Patel, P.D.; Sant, G.; Meng, C.X.; Teng, K.K.; Hempstead, B.L.; Lee, F.S. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. *J. Neurosci.* 2004, 24, 4401–4411. [CrossRef] [PubMed]

114. Chiaruttini, C.; Vicario, A.; Li, Z.; Baj, G.; Braiuca, P.; Wu, Y.; Lee, F.S.; Gardossi, L.; Baraban, J.M.; Tongiorgi, E. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. *Proc. Natl. Acad. Sci. USA* 2009, 106, 16481–16486. [CrossRef] [PubMed]

115. Tsai, S.J. Salivary gland low-intensity pulsed ultrasound (LIPUS) stimulation as a potential treatment for various BDNF-implicated neuropsychiatric disorders. *Med. Hypotheses* 2020, 137, 109560. [CrossRef] [PubMed]

116. Lin, C.C.; Huang, T.L. Brain-derived neurotrophic factor and mental disorders. *Biomed. J.* 2020, 43, 134–142. [CrossRef] [PubMed]

117. Di Lazzaro, V.; Pellegrino, G.; Di Pino, G.; Corbetto, M.; Ranieri, F.; Brunelli, N.; Paolucci, M.; Bucossi, S.; Ventriglia, M.C.; Brown, P.; et al. Val66Met BDNF gene polymorphism influences human motor cortex plasticity in acute stroke. *Brain Stimul.* 2015, 8, 92–96. [CrossRef]
118. Morin-Moncet, O.; Latulipe-Loiselle, A.; Therrien-Blanchet, J.M.; Theoret, H. BDNF Val66Met polymorphism is associated with altered activity-dependent modulation of short-interval intracortical inhibition in bilateral M1. PLoS ONE 2018, 13, e0197505. [CrossRef]

119. Hashimoto, T.; Fukui, K.; Takeuchi, H.; Yokota, S.; Kikuchi, Y.; Tomita, H.; Taki, Y.; Kawashima, R. Effects of the BDNF Val66Met Polymorphism on Gray Matter Volume in Typically Developing Children and Adolescents. Cereb. Cortex 2016, 26, 1795–1803. [CrossRef]

120. Meng, W.D.; Sun, S.J.; Yang, J.; Chu, R.X.; Tu, W.; Liu, Q. Elevated Serum Brain-Derived Neurotrophic Factor (BDNF) but not BDNF Gene Val66Met Polymorphism Is Associated with Autism Spectrum Disorders. Mol. Neurobiol. 2017, 54, 1167–1172. [CrossRef]

121. Montag, C.; Basten, U.; Stelzel, C.; Fiebach, C.J.; Reuter, M. The BDNF Val66Met polymorphism and anxiety: Support for animal knock-in studies from a genetic association study in humans. Psychiatry Res. 2010, 179, 86–90. [CrossRef] [PubMed]

122. Park, C.H.; Kim, J.; Namgung, E.; Lee, D.W.; Kim, G.H.; Kim, M.; Kim, N.; Kim, T.D.; Kim, S.; Lyoo, I.K.; et al. The BDNF Val66Met Polymorphism Affects the Vulnerability of the Brain Structural Network. Front. Hum. Neurosci. 2017, 11, 400. [CrossRef] [PubMed]

123. Hariri, A.R.; Goldberg, T.E.; Mattay, V.S.; Kolachana, B.S.; Callicott, J.H.; Egan, M.F.; Weinberger, D.R. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 2003, 23, 6690–6694. [CrossRef] [PubMed]

124. Pezawas, L.; Verchinski, B.A.; Mattay, V.S.; Callicott, J.H.; Kolachana, B.S.; Straub, R.E.; Egan, M.F.; Meyer-Lindenberg, A.; Weinberger, D.R. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J. Neurosci. 2004, 24, 10099–10102. [CrossRef] [PubMed]

125. Ho, B.C.; Milev, P.; O’Leary, D.S.; Librant, A.; Andresen, N.C.; Wassink, T.H. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry 2006, 63, 731–740. [CrossRef] [PubMed]

126. Montag, C.; Weber, B.; Fliessbach, K.; Elger, C.; Reuter, M. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: Incremental support for a genetic risk factor for depression. Psychol. Med. 2009, 39, 1831–1839. [CrossRef] [PubMed]

127. Xia, H.; Du, X.; Yin, G.; Zhang, Y.; Li, X.; Cai, J.; Huang, X.; Ning, Y.; Soares, J.C.; Wu, F.; et al. Effects of smoking on cognition and BDNF levels in a male Chinese population: Relationship with BDNF Val66Met polymorphism. Sci. Rep. 2019, 9, 217. [CrossRef]

128. Allmann, V.; Schumacher-Schuh, A.F.; Kieck, M.; Callegari-Jacques, S.M.; Rieder, C.R.; Hutz, M.H. Val66Met BDNF polymorphism is associated with Parkinson’s disease cognitive impairment. Neurosci. Lett. 2016, 615, 88–91. [CrossRef]

129. Wang, Q.; Liu, J.; Guo, Y.; Dong, G.; Zou, W.; Chen, Z. Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in Parkinson’s disease-a meta-analysis. Braz. J. Med. Biol. Res. 2019, 52, e8443. [CrossRef]

130. Franzmeier, N.; Ren, J.; Damm, A.; Monté-Rubio, G.; Boada, M.; Ruiz, A.; Ramirez, A.; Jessen, F.; Düzel, E.; Rodriguez Gómez, O.; et al. The BDNF Mol. Psychiatry 2019. [CrossRef]

131. Yin, Y.; Su, X.; Pan, L.; Li, C. BDNF Val66Met polymorphism and cognitive impairment in Parkinson’s disease: Effects of DNA methylation and reduced white matter integrity in late-onset depression and normal aging. Acta Psychiatr. Scand. 2013, 128, 387–396. [CrossRef] [PubMed]

132. Choi, S.; Han, K.M.; Won, E.; Yoon, B.J.; Lee, M.S.; Ham, B.J. Association of brain-derived neurotrophic factor DNA methylation and reduced white matter integrity in the anterior corona radiata in major depression. J. Affect. Disord. 2015, 172, 74–80. [CrossRef]

133. Youssef, M.M.; Underwood, M.D.; Huang, Y.Y.; Hsiung, S.C.; Liu, Y.; Simpson, N.R.; Bakalian, M.J.; Rosoklija, G.B.; Dwork, A.J.; Arango, V.; et al. Association of BDNF Val66Met Polymorphism and Brain BDNF Levels with Major Depression and Suicide. Int. J. Neuropsychopharmacol. 2018, 21, 528–538. [CrossRef]

134. Caldieraro, M.A.; McKee, M.; Leistner-Segal, S.; Vares, E.A.; Kubaski, F.; Spanenberg, L.; Brusius-Facchin, A.C.; Fleck, M.P.; Mischoulon, D. Val66Met polymorphism association with serum BDNF and inflammatory biomarkers in major depression. World J. Biol. Psychiatry 2018, 19, 402–409. [CrossRef]
136. Rong, C.; Park, C.; Rosenblat, J.D.; Subramaniapillai, M.; Zuckerman, H.; Fus, D.; Lee, Y.L.; Pan, Z.; Brietzke, E.; Mansur, R.B.; et al. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. *Int. J. Environ. Res. Public Health* 2018, 15, 771. [CrossRef]  
137. Mandolini, G.M.; Lazzaretti, M.; Pigoni, A.; Delvecchio, G.; Soares, J.C.; Brambilla, P. The impact of BDNF Val66Met polymorphism on cognition in Bipolar Disorder: A review: Special Section on “Translational and Neuroscience Studies in Affective Disorders”Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. *J. Affect. Disord.* 2019, 243, 552–558. [CrossRef]  
138. Chen, N.C.; Chuang, Y.C.; Huang, C.W.; Lui, C.C.; Lee, C.C.; Hsu, S.W.; Lin, P.H.; Lu, Y.T.; Chang, Y.T.; Hsu, C.W.; et al. Interictal serum brain-derived neurotrophic factor level reflects white matter integrity, epilepsy severity, and cognitive dysfunction in chronic temporal lobe epilepsy. *Epilepsy Behav.* 2016, 59, 147–154. [CrossRef] [PubMed]  
139. Sidhu, M.K.; Thompson, P.J.; Wandschneider, B.; Foulkes, A.; de Tisi, J.; Stretton, J.; Perona, M.; Thom, M.; Bonelli, S.B.; Burdett, J.; et al. The impact of brain-derived neurotrophic factor Val66Met polymorphism on cognition and functional brain networks in patients with intractable partial epilepsy. *CNS Neurosci. Ther.* 2019, 25, 223–232. [CrossRef] [PubMed]  
140. Doherty, C.; Hogue, O.; Floden, D.P.; Altemus, J.B.; Najm, I.M.; Eng, C.; Busch, R.M. BDNF and COMT, but not APOE, alleles are associated with psychiatric symptoms in refractory epilepsy. *Epilepsy Behav.* 2019, 94, 131–136. [CrossRef]  
141. Kheirrollahi, M.; Kazemi, E.; Ashouri, S. Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Risk of Schizophrenia: A Meta-analysis of Case-Control Studies. *Cell. Mol. Neurobiol.* 2016, 36, 1–10. [CrossRef] [PubMed]  
142. Xia, H.; Zhang, G.; Du, X.; Zhang, Y.; Yin, G.; Dai, J.; He, M.X.; Soares, J.C.; Li, X.; Zhang, X.Y. Suicide attempt, clinical correlates, and BDNF Val66Met polymorphism in chronic patients with schizophrenia. *Neuropsychology* 2018, 32, 199–205. [CrossRef]  
143. Huang, E.; Hettige, N.C.; Zai, G.; Tomasi, J.; Huang, J.; Zai, C.C.; Picav, N.; Nikolac Perkovic, M.; Tiwari, A.K.; Kennedy, J.L. BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: A meta-analysis. *Pharmacogenomics J.* 2019, 19, 269–276. [CrossRef] [PubMed]  
144. Han, M.; Deng, C. BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. *Neurosci. Lett.* 2020, 726, 133870. [CrossRef]  
145. Brown, A.; Machan, J.T.; Hayes, L.; Zervas, M. Molecular organization and timing of Wnt1 expression define cohorts of midbrain dopamine neuron progenitors in vivo. *J. Comp. Neurol.* 2011, 519, 2978–3000. [CrossRef]  
146. Ramos-Cejudo, J.; Gutiérrez-Fernández, M.; Otero-Ortega, L.; Rodriguez-Frutos, B.; Fuentes, B.; Vallejo-Cremades, M.T.; Hernandez, T.N.; Cerdán, S.; Diez-Tejedor, E. Brain-derived neurotrophic factor administration mediated oligodendrocyte differentiation and myelin formation in subcortical ischemic stroke. *Stroke* 2015, 46, 221–228. [CrossRef]  
147. Balkaya, M.; Cho, S. Genetics of stroke recovery: BDNF val66met polymorphism in stroke recovery and its interaction with aging. *Neurobiol. Dis.* 2019, 126, 36–46. [CrossRef]  
148. Lohia, R.; Salari, R.; Brannigan, G. Sequence specificity despite intrinsic disorder: How a disease-associated Val/Met polymorphism rearranges tertiary interactions in a long disordered protein. *PLoS Comput. Biol.* 2019, 15, e1007390. [CrossRef]  
149. Rock, P.L.; Roiser, J.P.; Riedel, W.J.; Blackwell, A.D. Cognitive impairment in depression: A systematic review and meta-analysis. *Psychol. Med.* 2014, 44, 2029–2040. [CrossRef]  
150. Severino, V.; Farina, A.; Colucci-D’Amato, L.; Reccia, M.G.; Volpicelli, F.; Parente, A.; Chambery, A. Secretome profiling of differentiated neural mes-c-myc A1 cell line endowed with stem cell properties. *Biochim. Biophys. Acta* 2013, 1834, 2385–2395. [CrossRef]  
151. Colucci-D’Amato, L.; Farina, A.; Vissers, J.P.; Chambery, A. Quantitative neuroproteomics: Classical and novel tools for studying neural differentiation and function. *Stem Cell Rev. Rep.* 2011, 7, 77–93. [CrossRef]
152. Di Lieto, A.; Leo, D.; Volpicelli, F.; di Porzio, U.; Colucci-D’Amato, L. FLUOXETINE modifies the expression of serotonergic markers in a differentiation-dependent fashion in the mesencephalic neural cell line A1 mes c-myc. Brain Res. 2007, 1143, 1–10. [CrossRef] [PubMed]

153. Nawa, Y.; Kaneko, H.; Oda, M.; Tsuobonoya, M.; Hiroi, T.; Gentile, M.T.; Colucci-D’Amato, L.; Takahashi, R.; Matsui, H. Functional characterization of the neuron-restrictive silencer element in the human tryptophan hydroxylase 2 gene expression. J. Neurochem. 2017, 142, 827–840. [CrossRef] [PubMed]

154. Gentile, M.T.; Nawa, Y.; Lunardi, G.; Florio, T.; Matsui, H.; Colucci-D’Amato, L. Tryptophan hydroxylase 2 (TPH2) in a neuronal cell line: Modulation by cell differentiation and NRSF/REST activity. J. Neurochem. 2012, 123, 963–970. [CrossRef] [PubMed]

155. Duman, R.S.; Heninger, G.R.; Nestler, E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54, 597–606. [CrossRef] [PubMed]

156. Colucci-D’Amato, L.; di Porzio, U. Neurogenesis in adult CNS: From denial to opportunities and challenges for therapy. Bioessays 2008, 30, 135–145. [CrossRef] [PubMed]

157. Colucci-D’Amato, L.; Bonavita, V.; di Porzio, U. The end of the central dogma of neurobiology: Stem cells and neurogenesis in adult CNS. Neuronal. Sci. 2006, 27, 266–270. [CrossRef] [PubMed]

158. Craver, S.C.; Sur, M.; Dobkin, B.H.; O’Brien, C.; Sanger, T.D.; Trojanowski, J.Q.; Rumsey, J.M.; Hicks, R.; Cameron, J.; Chen, D.; et al. Harnessing neuroplasticity for clinical applications. Brain 2011, 134, 1591–1609. [CrossRef]

159. Castrén, E. Neuronal network plasticity and recovery from depression. JAMA Psychiatry 2013, 70, 983–989. [CrossRef]

160. Snapyan, M.; Lemasson, M.; Brill, M.S.; Blais, M.; Massouh, M.; Ninkovic, J.; Gravel, C.; Berthod, F.; Götz, M.; Barker, P.A.; et al. Vasculature guides migrating neuronal precursors in the adult mammalian forebrain via brain-derived neurotrophic factor signaling. J. Neurosci. 2009, 29, 4172–4188. [CrossRef]

161. Bergami, M.; Rimondini, R.; Santi, S.; Blum, R.; Götz, M.; Canossa, M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc. Natl. Acad. Sci. USA 2008, 105, 15570–15575. [CrossRef] [PubMed]

162. Chan, K.L.; Tong, K.Y.; Yip, S.P. Relationship of serum brain-derived neurotrophic factor (BDNF) and health-related lifestyle in healthy human subjects. Neurosci. Lett. 2008, 447, 124–128. [CrossRef]

163. Zafra, F.; Lindholm, D.; Castrén, E.; Hartikka, J.; Thoenen, H. Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J. Neurosci. 1992, 12, 4793–4799. [CrossRef] [PubMed]

164. Castrén, E.; Antila, H. Neuronal plasticity and neurotrophic factors in drug responses. Mol. Psychiatry 2017, 22, 1085–1095. [CrossRef] [PubMed]

165. Castrén, E.; Zafra, F.; Thoenen, H.; Lindholm, D. Light regulates expression of brain-derived neurotrophic factor mRNA in rat visual cortex. Proc. Natl. Acad. Sci. USA 1992, 89, 9444–9448. [CrossRef] [PubMed]

166. Gianfranceschi, L.; Siciliano, R.; Walls, J.; Morales, B.; Kirkwood, A.; Huang, Z.J.; Tonegawa, S.; Ma, J.; Mons, J. Pharmacological characterization of six trkB antibodies reveals a novel component of Bdnf transcription in the development of cortical inhibition. Front. Behav. Neurosci. 2014, 8, 318. [CrossRef]

167. Cramer, S.C.; Sur, M.; Dobkin, B.H.; O’Brien, C.; Sanger, T.D.; Trojanowski, J.Q.; Rumsey, J.M.; Hicks, R.; Cameron, J.; Chen, D.; et al. Harnessing neuroplasticity for clinical applications. Brain 2011, 134, 1591–1609. [CrossRef]

168. Hong, E.J.; McCord, A.E.; Greenberg, M.E. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. Neuron 2008, 60, 610–624. [CrossRef]

169. Volpicelli, F.; Speranza, L.; di Porzio, U.; Crispino, M.; Perrone-Capano, C. The serotonin receptor 7 and the structural plasticity of brain circuits. Front. Behav. Neurosci. 2014, 8, 318. [CrossRef]

170. Cesroz, M.; Arrang, J.M.; Prémont, J. Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor. Br. J. Pharmacol. 2011, 162, 947–960. [CrossRef]

171. Park, S.W.; Nhu, I.H.; Cho, H.Y.; Seo, M.K.; Lee, C.H.; Ly, N.N.; Choi, C.M.; Lee, B.J.; Kim, G.M.; Seol, W.; et al. p11 mediates the BDNF-protective effects in dendritic outgrowth and spine formation in B27-deprived primary hippocampal cells. J. Affect. Disord. 2016, 196, 1–10. [CrossRef]

172. Katoh-Semba, R.; Asano, T.; Ueda, H.; Morishita, R.; Takeuchi, I.K.; Inaguma, Y.; Kato, K. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J. 2002, 16, 1328–1330. [CrossRef]
173. Cavanaugh, J.E.; Ham, J.; Hetman, M.; Poser, S.; Yan, C.; Xia, Z. Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J. Neurosci. 2001, 21, 434–443. [CrossRef]  
174. Lin, E.; Cavanaugh, J.E.; Leak, R.K.; Perez, R.G.; Zigmond, M.J. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J. Neurosci. Res. 2008, 86, 108–117. [CrossRef] [PubMed]  
175. Mariga, A.; Zavadil, J.; Ginsberg, S.D.; Chao, M.V. Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function. Dev. Neurobiol. 2015, 75, 173–192. [CrossRef]  
176. Mariga, A.M.; Li, C.J.; Gal Toth, J.; Bath, K.G.; Jing, D.; Lee, F.S.; McEwen, B.S. E
dentate gyrus granule neurons show impaired dendritic development and synaptic formation of postnatal-born neurons in the presence of brain-derived neurotrophic factor signaling. Exp. Neurol. 2009, 215, 178–190. [CrossRef]  
177. Mariga, A.; Zavadil, J.; Ginsberg, S.D.; Chao, M.V. Withdrawal of BDNF from hippocampal cultures leads to changes in genes involved in synaptic function. Dev. Neurobiol. 2015, 75, 173–192. [CrossRef]  
178. Mariga, A.M.; Li, C.J.; Gal Toth, J.; Bath, K.G.; Jing, D.; Lee, F.S.; McEwen, B.S. E
dentate gyrus granule neurons show impaired dendritic development and synaptic formation of postnatal-born neurons in the presence of brain-derived neurotrophic factor signaling. Exp. Neurol. 2009, 215, 178–190. [CrossRef]  
179. Aarse, J.; Herlitze, S.; Manahan-Vaughan, D. The requirement of BDNF for hippocampal synaptic plasticity is experience-dependent. Hippocampus 2016, 26, 739–751. [CrossRef]  
180. Magariños, A.M.; Li, C.J.; Gal Toth, J.; Bath, K.G.; Jing, D.; Lee, F.S.; McEwen, B.S. E
dentate gyrus granule neurons show impaired dendritic development and synaptic formation of postnatal-born neurons in the presence of brain-derived neurotrophic factor signaling. Exp. Neurol. 2009, 215, 178–190. [CrossRef]  
181. von Bohlen Und Halbach, O.; von Bohlen Und Halbach, V. BDNF e
dentate gyrus granule neurons show impaired dendritic development and synaptic formation of postnatal-born neurons in the presence of brain-derived neurotrophic factor signaling. Exp. Neurol. 2009, 215, 178–190. [CrossRef]  
182. von Bohlen Und Halbach, O.; Minichiello, L.; Unsicker, K. TrkB but not trkC receptors are necessary for successful treatment of mood disorders: A systematic & quantitative meta-analysis. J. A
dentate gyrus granule neurons show impaired dendritic development and synaptic formation of postnatal-born neurons in the presence of brain-derived neurotrophic factor signaling. Exp. Neurol. 2009, 215, 178–190. [CrossRef]  
183. Dokter, M.; Busch, R.; Poser, R.; Vogt, M.A.; von Bohlen Und Halbach, V.; Gass, P.; Unsicker, K.; von Bohlen Und Halbach, O. Implications of p75NTR for dentate gyrus morphology and hippocampus-related behavior revisited. Brain Struct. Funct. 2015, 220, 1449–1462. [CrossRef]  
184. Lin, P.Y.; Kavalali, E.T.; Monteggia, L.M. Genetic Dissection of Presynaptic and Postsynaptic BDNF-TrkB Signaling in Synchronous Efficacy of CA3-CA1 Synapses. Cell Rep. 2018, 24, 1550–1561. [CrossRef]  
185. Eyman, M.; Cefalù, C.; Mandile, P.; Piscopo, S.; Crispino, M.; Giuditta, A. Training old rats selectively modulates synaptosomal protein synthesis. J. Neurosci. Res. 2013, 91, 20–29. [CrossRef]  
186. Nikoletopoulou, V.; Sidiropoulou, K.; Kallergi, E.; Daleriozis, Y.; Tavernarakis, N. Modulation of Autophagy by BDNF Underlies Synchronous Plasticity. Cell Metab. 2017, 26, 230–242. [CrossRef]  
187. Fujimura, H.; Altar, C.A.; Chen, R.; Nakamura, T.; Nakahashi, T.; Kambayashi, J.; Sun, B.; Tandon, N.N. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb. Haemost. 2002, 87, 728–734. [CrossRef]  
188. Klein, A.B.; Williamson, R.; Santini, M.A.; Clemmensen, C.; Etrup, A.; Rios, M.; Knudsen, G.M.; Aznar, S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol. 2011, 14, 347–353. [CrossRef]  
189. Mondal, A.C.; Fatima, M. Direct and indirect evidences of BDNF and NGF as key modulators in depression: Role of antidepressants treatment. Int. J. Neuropsychopharmacol. 2019, 22, 283–296. [CrossRef]  
190. Molendijk, M.L.; Spinthoven, P.; Polak, M.; Bus, B.A.; Penninx, B.W.; Elzinga, B.M. Serum BDNF concentrations as peripheral manifestations of depression: Evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol. Psychiatry 2014, 19, 791–800. [CrossRef]  
191. Polyakova, M.; Stuke, K.; Schuemberg, K.; Mueller, K.; Schoenknecht, P.; Schroeter, M.L. BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis. J. Affect. Disord. 2015, 174, 432–440. [CrossRef] [PubMed]  
192. Kishi, T.; Yoshimura, R.; Ikuta, T.; Iwata, N. Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses. Front. Psychiatry 2017, 8, 308. [CrossRef] [PubMed]  
193. Serra-Millàs, M. Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation? World J. Psychiatry 2016, 6, 84–101. [CrossRef] [PubMed]
194. Allen, A.P.; Naughton, M.; Dowling, J.; Walsh, A.; Ismail, F.; Shorten, G.; Scott, L.; McLoughlin, D.M.; Cryan, J.F.; Dinan, T.G.; et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. *J. Affect. Disord.* **2015**, *186*, 306–311. [CrossRef]

195. Lee, B.H.; Kim, Y.K. Reduced platelet BDNF level in patients with major depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2009**, *33*, 849–853. [CrossRef]

196. Dwivedi, Y. The Neurobiological Basis of Suicide; CRC Press: Boca Raton, FL, USA, 2012.

197. Pandey, G.N.; Dwivedi, Y.; Rizavi, H.S.; Ren, X.; Zhang, H.; Pavuluri, M.N. Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2010**, *34*, 645–651. [CrossRef]

198. Palacios, I.; Navarro, V.; Galán, A.M.; Escolar, G.; Penadés, R.; Catalán, R.; Fañanás, L.; Arias, B.; Gascó, C. Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression. *Psychopharmacology* **2011**, *216*, 1–8. [CrossRef]

199. Pandey, G.N.; Dwivedi, Y.; Conley, R.R.; Roberts, R.C.; Dwivedi, Y. Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. *Int. J. Neuropsychopharmacol.* **2008**, *11*, 1047–1061. [CrossRef]

200. Hosang, G.M.; Shiles, C.; Tansey, K.E.; McGuffin, P.; Uher, R. Interaction between stress and the BDNF Val66Met polymorphism in depression: A systematic review and meta-analysis. *BMC Med.* **2014**, *12*, 7. [CrossRef]

201. Li, M.; Du, W.; Shao, F.; Wang, W. Cognitive dysfunction and epigenetic alterations of the BDNF gene are induced by social isolation during early adolescence. *Behav. Brain Res.* **2016**, *313*, 177–183. [CrossRef]

202. Yan, T.; Wang, L.; Kuang, W.; Xu, J.; Li, S.; Chen, J.; Yang, Y. Brain-derived neurotrophic factor Val66Met polymorphism association with antidepressant efficacy: A systematic review and meta-analysis. *Asia Pac. Psychiatry* **2014**, *6*, 241–251. [CrossRef]

203. Castrén, E.; Rantamäki, T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. *Dev. Neurobiol.* **2010**, *70*, 289–297. [CrossRef] [PubMed]

204. Crispino, M.; Volpicelli, F.; Perrone-Capano, C. Role of the Serotonin Receptor 7 in Brain Plasticity: From Development to Disease. *Int. J. Mol. Sci.* **2020**, *21*, 505. [CrossRef] [PubMed]

205. Alenina, N.; Klempin, F. The role of serotonin in adult hippocampal neurogenesis. *Behav. Brain Res.* **2015**, *277*, 49–57. [CrossRef] [PubMed]

206. Malberg, J.E.; Eisch, A.J.; Nestler, E.J.; Duman, R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J. Neurosci.* **2000**, *20*, 9104–9110. [CrossRef] [PubMed]

207. Santarelli, L.; Saxe, M.; Goss, C.; Surget, A.; Battaglia, F.; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O.; et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* **2003**, *301*, 805–809. [CrossRef]

208. Rantamäki, T.; Castrén, E. Targeting TrkB neurotrophin receptor to treat depression. *Expert Opin. Ther. Targets* **2008**, *12*, 705–715. [CrossRef] [PubMed]

209. Speranza, L.; Labus, J.; Volpicelli, F.; Guseva, D.; Lacivita, E.; Leopoldo, M.; Bellenchi, G.C.; di Porzio, U.; Bijata, M.; Perrone-Capano, C.; et al. Serotonin 5-HT17 receptor increases the density of dendritic spines and facilitates synaptogenesis in forebrain neurons. *J. Neurochem.* **2017**, *141*, 647–661. [CrossRef]

210. Speranza, L.; Giuliani, T.; Volpicelli, F.; De Stefano, M.E.; Lombardi, L.; Chambery, A.; Lacivita, E.; Leopoldo, M.; Bellenchi, G.C.; di Porzio, U.; et al. Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics. *Front. Behav. Neurosci.* **2015**, *9*, 62. [CrossRef]

211. Speranza, L.; Chambery, A.; Di Domenico, M.; Crispino, M.; Severino, V.; Volpicelli, F.; Leopoldo, M.; Bellenchi, G.C.; di Porzio, U.; Perrone-Capano, C. The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways. *Neuropsychopharmacology* **2013**, *38*, 155–167. [CrossRef]

212. Popova, N.K.; Naumenko, V.S. Neuronal and behavioral plasticity: The role of serotonin and BDNF systems tandem. *Expert Opin. Ther. Targets* **2019**, *23*, 227–239. [CrossRef] [PubMed]

213. Castrén, E. Neurotrophins and psychiatric disorders. *Handb. Exp. Pharmacol.* **2014**, *220*, 461–479. [CrossRef] [PubMed]

214. Castrén, E.; Kojima, M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. *Neurobiol. Dis.* **2017**, *97*, 119–126. [CrossRef] [PubMed]
215. Castrén, E.; Rantamäki, T. Role of brain-derived neurotrophic factor in the aetiology of depression: Implications for pharmacological treatment. CNS Drugs 2010, 24, 1–7. [CrossRef]

216. Lepack, A.E.; Fuchikami, M.; Dwyer, J.M.; Banasr, M.; Duman, R.S. BDNF release is required for the behavioral actions of ketamine. Int. J. Neuropsychopharmacol. 2014, 18. [CrossRef]

217. Abdallah, C.G.; Sanacora, G.; Duman, R.S.; Krystal, J.H. Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 2015, 66, 509–523. [CrossRef][PubMed]

218. Liu, R.J.; Lee, F.S.; Li, X.Y.; Bambico, F.; Duman, R.S.; Aghajanian, G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 2012, 71, 996–1005. [CrossRef]

219. Kato, T.; Fogaça, M.V.; Dyeyama, S.; Li, X.Y.; Fukumoto, K.; Duman, R.S. BDNF release and signaling are required for the antidepressant actions of GLYX-13. Mol. Psychiatry 2018, 23, 2007–2017. [CrossRef]

220. Liu, R.J.; Lee, F.S.; Li, X.Y.; Bambico, F.; Duman, R.S.; Aghajanian, G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 2012, 71, 996–1005. [CrossRef]

221. Herring, M.P.; Puetz, T.W.; O’Connor, P.J.; Dishman, R.K. Exercise-dependent BDNF as a Modulatory Factor for the Executive Processing of Individuals in Course of Cognitive Decline. A Systematic Review. Front. Psychol. 2017, 8, 584. [CrossRef][PubMed]

222. Hoshaw, B.A.; Malberg, J.E.; Lucki, I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005, 1037, 204–208. [CrossRef]

223. Saarelainen, T.; Hendolin, P.; Lucas, G.; Saarinen, M.; MacDonald, E.; Agerman, K.; Haapasalo, A.; Nawa, H.; Aloyz, R.; et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 2003, 23, 349–357. [CrossRef][PubMed]

224. Liu, R.J.; Lee, F.S.; Li, X.Y.; Bambico, F.; Duman, R.S.; Aghajanian, G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 2012, 71, 996–1005. [CrossRef]

225. Kato, T.; Fogaça, M.V.; Dyeyama, S.; Li, X.Y.; Fukumoto, K.; Duman, R.S. BDNF release and signaling are required for the antidepressant actions of GLYX-13. Mol. Psychiatry 2018, 23, 2007–2017. [CrossRef]

226. Monteggia, L.M.; Barrot, M.; Powell, C.M.; Berton, O.; Galanis, V.; Meuth, S.; Nagy, A.; Greene, R.W.; Nestler, E.J. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. USA 2004, 101, 10827–10832. [CrossRef][PubMed]

227. Hoshaw, B.A.; Malberg, J.E.; Lucki, I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005, 1037, 204–208. [CrossRef]

228. Monteggia, L.M.; Zanata, C. Antidepressant actions of ketamine: From molecular mechanisms to clinical practice. Curr. Opin. Neurobiol. 2015, 30, 139–143. [CrossRef][PubMed]

229. Björkholm, C.; Monteggia, L.M. BDNF—a key transducer of antidepressant effects. Neuropharmacology 2016, 102, 72–79. [CrossRef][PubMed]

230. Abdallah, C.G.; Sanacora, G.; Duman, R.S.; Krystal, J.H. Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 2015, 66, 509–523. [CrossRef][PubMed]

231. Castrén, E.; Rantamäki, T. Role of brain-derived neurotrophic factor in the aetiology of depression: Implications for pharmacological treatment. CNS Drugs 2010, 24, 1–7. [CrossRef]
235. Pajonk, F.G.; Wobrock, T.; Gruber, O.; Scherk, H.; Berner, D.; Kaizl, I.; Kierer, A.; Müller, S.; Oest, M.; Meyer, T.; et al. Hippocampal plasticity in response to exercise in schizophrenia. *Arch. Gen. Psychiatry* 2010, 67, 133–143. [CrossRef] [PubMed]

236. Moon, H.Y.; Becke, A.; Berron, D.; Becker, B.; Sah, N.; Benoni, G.; Janke, E.; Lubejko, S.T.; Greig, N.H.; Mattison, J.A.; et al. Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory Function. *Cell Metab.* 2016, 24, 332–340. [CrossRef] [PubMed]

237. Boström, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; Rasbach, K.A.; Boström, E.A.; Choi, J.H.; Long, J.Z.; et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature* 2012, 481, 463–468. [CrossRef]

238. Wrann, C.D.; White, J.P.; Salogiannnis, J.; Laznik-Bogoslavski, D.; Wu, J.; Ma, D.; Lin, J.D.; Greenberg, M.E.; Spiegelman, B.M. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. *Cell Metab.* 2013, 18, 649–659. [CrossRef]

239. Müller, P.; Duderstadt, Y.; Lessmann, V.; Müller, N.G. Lactate and BDNF: Key Mediators of Exercise Induced Neuroplasticity? *J. Clin. Med.* 2020, 9, 1136. [CrossRef]

240. Piotrowicz, Z.; Chalimoniuk, M.; Płoszczyca, K.; Czuba, M.; Langfort, J. Exercise-Induced Elevated BDNF Level Does Not Prevent Cognitive Impairment Due to Acute Exposure to Moderate Hypoxia in Well-Trained Athletes. *Int. J. Mol. Sci.* 2020, 21, 5569. [CrossRef]

241. Miranda, M.; Morici, J.F.; Zanoni, M.B.; Bekinschtein, P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. *Front. Cell Neurosci.* 2019, 13, 363. [CrossRef]

242. Hock, C.; Heese, K.; Hulette, C.; Rosenberg, C.; Otten, U. Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. *Arch. Neurol.* 2000, 57, 846–851. [CrossRef]

243. Zuccato, C.; Marullo, M.; Conforti, P.; MacDonald, M.E.; Tartari, M.; Cattaneo, E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington’s disease. *Brain Pathol.* 2008, 18, 225–238. [CrossRef] [PubMed]

244. Nairisawa-Saito, M.; Wakabayashi, K.; Tsuji, S.; Takahashi, H.; Nawa, H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer’s disease. *Neuroreport* 1996, 7, 2925–2928. [CrossRef]

245. Hoxha, E.; Lippiello, P.; Zurlo, F.; Balbo, I.; Santamaria, R.; Tempia, F.; Miniaci, M.C. The Emerging Role of Altered Cerebellar Synaptic Processing in Alzheimer’s Disease. *Front. Aging Neurosci.* 2018, 10, 396. [CrossRef] [PubMed]

246. Peng, S.; Wuw, J.; Mufson, E.J.; Fahnstock, M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. *J. Neurochem.* 2005, 93, 1412–1421. [CrossRef] [PubMed]

247. Choi, S.H.; Bylykbashi, E.; Chatila, Z.K.; Lee, S.W.; Pulli, B.; Clemenson, G.D.; Kim, E.; Rompala, A.; Oram, M.K.; Asselin, C.; et al. Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer’s mouse model. *Science* 2018, 361. [CrossRef] [PubMed]

248. Sleiman, S.F.; Bany-Haddad, R.; El Hayek, L.; Abou Haidar, E.; Stringer, T.; Ulja, D.; Karuppagounder, S.S.; Holson, E.B.; Ratan, R.R.; et al. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate. *Elife* 2016, 5. [CrossRef] [PubMed]

249. Colucci-D’Amato, L.; Perrone-Capano, C.; di Porzio, U. Chronic activation of ERK and neurodegenerative diseases. *Bioessays* 2003, 25, 1085–1095. [CrossRef] [PubMed]

250. Kirouac, L.; Rajic, A.J.; Cribbs, D.H.; Padmanabhan, J. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer’s Disease. *eNeuro* 2017, 4. [CrossRef]

251. Nizzari, M.; Barbieri, F.; Gentile, M.T.; Passarella, D.; Caorsi, C.; Diaspro, A.; Taglialetela, M.; Pagano, A.; Colucci-D’Amato, L.; Florio, T.; et al. Amyloid-β protein precursor regulates phosphorylation and cellular compartmentalization of microtubule associated protein tau. *J. Alzheimer Dis.* 2012, 29, 211–227. [CrossRef]

252. Bartolotti, N.; Segura, L.; Lazarov, O. Diminished CRE-Induced Plasticity is Linked to Memory Deficits in Familial Alzheimer’s Disease Mice. *J. Alzheimer Dis.* 2016, 50, 477–489. [CrossRef] [PubMed]

253. Rosa, E.; Fahnstock, M. CREB expression mediates amyloid β-induced basal BDNF downregulation. *Neurobiol. Aging* 2015, 36, 2406–2413. [CrossRef] [PubMed]
254. Thiele, C.J.; Li, Z.; McKee, A.E. On Trk—the TrkB signal transduction pathway is an increasingly important target in cancer biology. *Clin. Cancer Res.* **2009**, *15*, 5962–5967. [CrossRef] [PubMed]

255. Xiong, J.; Zhou, L.I.; Lim, Y.; Yang, M.; Zhu, Y.H.; Li, Z.W.; Fu, D.L.; Zhou, X.F. Mature brain-derived neurotrophic factor and its receptor TrkB are upregulated in human glioma tissues. *Oncol. Lett.* **2015**, *10*, 223–227. [CrossRef] [PubMed]

256. Colucci-D’Amato, G.L.; D’Alessio, A.; Califano, D.; Cali, G.; Rizzo, C.; Nitsch, L.; Santelli, G.; de Franciscis, V. Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK. *J. Biol. Chem.* **2000**, *275*, 19306–19314. [CrossRef]

257. Radin, D.P.; Patel, P. BDNF: An Oncogene or Tumor Suppressor? *Anticancer. Res.* **2017**, *37*, 3983–3990. [CrossRef]

258. Wang, X.; Prager, B.C.; Wu, Q.; Kim, L.J.Y.; Gimple, R.C.; Shi, Y.; Yang, K.; Morton, A.R.; Zhou, W.; Zhu, Z.; et al. Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. *Cell Stem Cell* **2018**, *22*, 514–528. [CrossRef]

259. Garofalo, S.; D’Alessandro, G.; Chece, G.; Brau, F.; Maggi, L.; Rosa, A.; Porzia, A.; Mainiero, F.; Esposito, V.; Lauro, C.; et al. Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice. *Nat. Commun.* **2015**, *6*, 6623. [CrossRef]

260. Garofalo, S.; Porzia, A.; Mainiero, F.; Di Angelantonio, S.; Cortese, B.; Basilico, B.; Pagani, F.; Cignitti, G.; Chece, G.; Maggio, R.; et al. Environmental stimuli shape microglial plasticity in glioma. *Elife* **2017**, *6*. [CrossRef]

261. Colucci-D’Amato, L.; Cimaglia, G. As a potential source of neuroactive compounds to promote and restore neural functions. *J. Tradit. Complement. Med.* **2020**, *10*, 309–314. [CrossRef]

262. Gentile, M.T.; Ciniglia, C.; Reccia, M.G.; Volpicelli, F.; Gatti, M.; Tellung, S.; Florio, T.; Melone, M.A.; Colucci-D’Amato, L. Ruta graveolens L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation. *PLoS ONE* **2015**, *10*, e0118864. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.